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Abstract
The process of white adipose tissue (WAT) browning has become a key
focus topic in adipobiology research, due to its fat burning potential in obe-
sity treatment. The interest in brown adipose tissue (BAT) derives from
its unique ability to generate heat by adaptive thermogenesis. This pro-
cess mediates the catabolism of energy substrates without the generation
of ATP. Therefore, energy dissipation by BAT can control obesity by lead-
ing excess fat towards heat production. While brown adipocytes are rich in
mitochondria and small lipid droplets (multilocular adipocytes), white ad-
ipocytes have few mitochondria and a single large lipid droplet (unilocular
adipocytes). Moreover, uncoupling protein 1, the main driver of thermogen-
esis, is present only on the inner mitochondrial membrane of brown adipoc-
ytes, where it uncouples the oxidative phosphorylation from ATP synthesis.
The research presented in this doctoral thesis involves the administra-
tion of endogenous and nutritional compounds to in vitro adipocyte models
to evaluate their potential in inducing WAT browning. The chosen com-
pounds are two myokines (β-aminoisobutyric acid and brain-derived neur-
otrophic factor) and two nutritional molecules (capsaicin and cis-9 retinoic
acid). The effectiveness and the long-term effects of these biocompounds
were here investigated in terms of lipid droplets and mitochondria struc-
tural changes on different cellular models.
The results hereby discussed confirmed the potential of these bioac-
tive compounds in inducing WAT browning, in agreement with previous
knowledge and bringing new insights in this research field. Novel observa-
tions concerning doses and time-dependent effects of these browning fac-
2
tors could direct future research towards a correct and effective implemen-
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Adipose tissue (AT) is a connective tissue composed by different cell
types. The main cells constituting AT are the lipid-accumulating adipocy-
tes. Other cell types include preadipocytes, macrophages, endothelial cells,
stem cells and nerve endings. Taken together, these cell types represent
the stromal-vascular fraction (SVF) [1].
Conventionally, AT is divided into two different subtypes: white adipose
tissue (WAT) and brown adipose tissue (BAT).
1.1 White adipose tissue
In past decades, WAT was associated to the sole function of passive stor-
age of excess energy coming from food in form of triacylglycerols (TAGs).
Afterwards, researches described the endocrine function of white adipoc-
ytes, able to produce a great variety of adipose-derived hormones and cy-
tokines, named adipokines, and to participate in the metabolism of sex hor-
mones [1].
From a histological point of view, WAT is composed by large adipocytes
(around 100 µm diameter) whose cytoplasm is almost entirely filled with
a unilocular lipid droplet (LD) that pushes the nucleus against the plasma
membrane. WAT forms depots in different parts of the body and the dis-
tribution of mass in each depot depends on genetics, age and sensitivity to
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glucocorticoids and other hormones [2]. According to the impact of WAT
depots on metabolic health, WAT can be divided into visceral WAT (vWAT)
and subcutaneous WAT (scWAT). Visceral WAT is associated to metabolic
disease, such as dyslipidemia, obesity, type 2 diabetes mellitus, cardiovas-
cular disease, hepatic steatosis and some forms of cancer; scWAT is associ-
ated with a decreased risk of developing metabolic syndrome [3].
Anatomically, WAT depots can be classified in mice as follows, according
to Waldén and colleagues [4] (Figure 1.1):
Figure 1.1: Localization of WAT and BAT depots in mouse, modified from Jung
et al. [5]
• anterior subcutaneous WAT (asWAT), which includes axillary and in-
terscapular fat;
• inguinal WAT (iWAT), dorsal to the pelvis;
• perigonadal WAT (pgWAT), which surroundes epididymis and testes
in male, ovaries and uterus in female;
• retroperitoneal WAT (rpWAT), which is in the abdominal cavity be-
hind kidneys;
• mesenteric WAT (mWAT), which surroundes visceral organs.
A similar classification is proposed for human WAT depots by Wronska et
al. [6] (Figure 1.2):
9
CHAPTER 1. THE ADIPOSE TISSUE
Figure 1.2: Localization of WAT fat pads in human, modified from Wronska et
al. [6]
• scWAT depots: subcutaneous abdominal, gluteal and femoral;
• vWAT depots: epicardial, mesenteric, omental, retroperitoneal and
gonadal.
The cellularity of WAT is determined in early life and renewal of senes-
cent adipocytes occurs constantly during lifetime [7], although the rate of
adipocyte turnover is still matter of debate [8–10]. Albeit adipocyte age and
turnover are not affected by body mass index (BMI) [9], cellular growth
and expansion are depot-specific and respond differently to high-fat diet
[11]. AT expansion by hyperplasia (i.e. increase of cellular number) is a
feature of scWAT in femoral and gluteal depots, while vWAT is more prone
to hypertrophy (i.e. increase of cellular volume) [12].
The excessive expansion of WAT depots is a pathological state known
as obesity, whose deleterious effects on whole body health state are a con-
sequence of the changes in adipocyte number and size [13]. Abdominal
adipocytes can increase their volume until they reach a critical size [14]
10
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before cell death occurs. When this happens, new preadipocytes are stim-
ulated to differentiate from SVF into mature adipocytes to increase the
storage capacity of the WAT depot. Adipocyte death recruits macrophages,
which remove the cellular debrits [15]. When multiple adipocytes reach
their critical size and face apoptosis, a high number of macrophages is re-
cruited and an inflammatory response is triggered in the depot [16]. This
causes the release of proinflammatory cytokines that alter the functional-
ity of living adipocytes and promote the synthesis of lipid mediators. These
molecules interfere with insulin signaling, eventually leading to the insur-
gence of insulin resistance and type 2 diabetes mellitus [16].
1.1.1 Origins of white adipocytes
Since mature adipocytes cannot divide by mitosis, the development of
new adipocytes involves progenitor cells located in SVF [2]. The presence
of different cell surface markers on SVF stem cells allows to distinguish
populations with the ability to give rise to functional adipocytes from those
which will not committ into fat cells; moreover, most of these markers are
depot-specific [11].
In past decades, it was rather spreaded the simplistic convintion that,
at embryonal level, adipocyte precursors were of exclusively mesodermic
origin [17]. Recent findings confirmed that adipocytes forming depots in
the cephalic area derive from at least two kinds of precursors in the neural
crest [18]. The neural crest Sox10+ adipogenic lineage is the main contrib-
utor to the cephalic depots [19]. Since they decrease with age, they are re-
placed by another lineage who shares similar metabolic profiles, hence the
derived differentiated adipocytes have the same characteristics [18]. More-
over, also bone marrow is a source of adipogenic precursors: experiments
of bone marrow transplants revealed that hematopoietic cells turned into
adipocytes in several depots in mice [20].
In adult AT, the main adipose progenitors are mesenchymal stem cells
11
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(MSCs) expressing platelet-derived growth factor receptor α (PDGFRα). Th-
ese cells can be either positive or negative for CD24. MSCs CD24+ appear
to be more committed to the adipogenic lineage, despite they are much less
frequent than CD24– ones [21, 22]. A subpopulation of perivascular MSCs
PDGFRα+ may give rise to both white and brown adipocytes. They express
Sca1 and CD34, but are negative for other pericyte markers [21].
Endothelial cells may become white or brown adipocytes as well: ZFP423+
cells can give rise to mature adipocytes [23]. Also VE-cadherin+ endothe-
lial cells may become adipogenic, but they are not evenly distributed [24].
An important study identified PDGFRβ+ mural cells in adipose SVF as adi-
pose progenitors, individuating the endothelium of adipose blood vessels as
a niche of future adipocytes [25]. These cells are committed to become fat
cells during embryonic life or in the perinatal period [25].
1.1.2 White adipogenesis
In many species, WAT formation begins before birth and then rapidly
increases in the post-natal life [26]. Adipose precursors are recruited from
stem cells and then differentiate into mature adipocytes through a process
named adipogenesis. The presence of different types of precursors in var-
ious WAT depots explains the depot-specific metabolic and growth differ-
ences [11]. The adipogenic machinery can be activated by different stimuli,
such as a number of extracellular factors including bone morphogenetic
proteins (BMPs), transforming growth factor β (TGFβ), insulin-like growth
factor 1 (IGF1) and different fibroblast growth factors (FGFs) [27]. The in-
hibition of anti-adipogenic Wnt [28] and hedgehog [29] signaling pathways
can also trigger adipogenesis (Figure 1.3). Moreover, intracellular path-
ways and regulators, such as glutathione, Janus kinase-signal transducer
and activator of transcription 3 (JAK-STAT3) and insulin transduction cas-
cade, have a role in favoring adipogenesis [27].
Pro-adipogenic stimuli upregulate the transcription of early adipogenic
12
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Figure 1.3: Transcriptional networks regulating adipogenesis in white fat cells.
IGF1: insulin-like growth factor; WNT10b: Wnt family member 10B;
SHH: sonic hedgehog signaling molecule; PTC: protein patched
homolog 1; SMO: smoothened; TGFβ: transforming growth factor β;
SMAD: mothers against decapentaplegic homolog; FGF: fibroblast
growth factor; FGFR: FGF receptor; BMPs: bone morphogenetic
proteins; IRS: insulin receptor substrate; MAPK: mitogen-activated
protein kinase; AR: androgen receptor; SHN2: schnurri-2; mTOR:
mammalian target of rapamycin; PI3K: phosphoinositide 3-kinase;
cAMP: cyclic adenosine monophosphate; AKT/PKB: protein kinase B;
CREB: cAMP-responsive element-binding protein; FOXO1: forkhead
box protein O1; FOXA2: forkhead box protein A2; TCF/LEF: T-cell
factor/lymphoid enhancer-binding factor; C/EBPα:
CAAT/enhancer-binding protein α; PPARγ: peroxisome
proliferator-activated receptor γ; GATA: globin transcription factor.
From Rosen & MacDougald [30].
factors CAAT/enhancer-binding protein β (C/EBPβ) and C/EBPδ. These
two proteins promote the synthesis of key adipogenic transcription fac-
tors C/EBPα, peroxisome proliferator-activated receptor γ (PPARγ), and
of sterol regulatory element binding protein 1 (SREBP1), which positively
regulate lipogenic genes. C/EBPα enhances PPARγ expression and vice
versa in a positive feedback loop (Figure 1.3). These elements are key reg-
ulators of adipogenesis because they affect the expression of a wide spec-
trum of genes involved in lipid metabolism and insulin sensitivity [27]. In
particular, PPARγ recruits different histone deacetylases (HDACs) and his-
tone acetyltransferases (HATs) that have multiple effects on adipogenesis-
related genes [31].
13
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The pro-adipogenic transcriptional network is tightly regulated by a
number of enhancing and inhibiting genes and factors, as reported in Fig-
ure 1.3, some of which have not been identified yet.
The epigenetic control of adipogenesis involves many histone-modificator
enzymes and a complex net of adipose-specific micro RNAs (miRNAs), in-
cluding both positive and negative regulators, as extensively reviewed by
Engin [32].
The transcriptional machinery that controls adipogenesis may slightly
vary between different depots: the ablation of certain adipogenic genes may
impair adipogenesis in some depots, while other ones are uneffected. The
only factor whose deletion is detrimental for all depots is PPARγ [7].
1.2 Brown adipose tissue
Numerous and important differences distinguish WAT from BAT. In-
deed, brown adipocytes have many unique morphological and phenotypic
characteristics. These cells are far smaller than white adipocytes (about 40
µm of diameter), with a circular central nucleus and lipids that are accu-
mulated in a high number of small LDs surrounded by a branched network
of mitochondria [33].
Among Mammals, BAT has a very different distribution, being mostly
displayed in rodents and hibernating animals. In humans, BAT was be-
lieved to be widespread in neonatal period and to disappear while going
through adult life. Only recently, active BAT has been observed in adult
humans following 18F-deoxyglucose positron emission tomography (18FDG
PET) combined with X-ray computerized tomography (CT) imaging [34–
36]. Unlike WAT depots, BAT is accumulated in few discrete regions in
adult human (Figure 1.4), which are richer in blood vessels and nerve end-
ings [37]. Subcutaneous BAT is present in the cervical area, flanking an-
terior neck muscles, in the anterior abdominal wall and in the inguinal re-
gion. A perivascular portion is also present around common carotid artery,
14
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aorta, brachiocephalic artery and epicardial coronary artery. Moreover, vis-
ceral BAT depots are present in close proximity of pericardium, kidneys,
adrenal glands, pancreas and liver.
Figure 1.4: Distribution of BAT depots compared to WAT ones in adult humans.
From Jeremic et al. [37].
In mice, BAT depots are found in interscapular, subscapular and cervi-
cal regions and surround portions of aorta and kidneys [2], as displayed in
Figure 1.1.
The functional significance of BAT resides in its ability to perform ther-
mogenesis, a process by which the catabolism of high energy substrates,
like fatty acids (FAs) or carbohydrates, is uncoupled from the synthesis of
ATP in mitochondria, hence the energy of these molecules is released in
form of heat [33]. The main driver of this process is the uncoupling pro-
tein 1 (UCP1), expressed in the inner mitochondrial membrane of brown
adipocytes [38].
1.2.1 Development of brown adipocytes
The main precursor of brown adipocytes is the same that can differenti-
ate into myocytes, but not into white fat cells [2]. These precursors express
15
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a whole set of pro-myogenic factors, including the myogenic factor 5 (Myf5)
[39]. The paired box factors 3 and 7 (Pax3 and Pax7) also contribute nor-
mally to myogenesis, thus are expressed in the BAT-committed progenitors
as well [40]. According to these observations, the developmental routes that
contribute to the formation of WAT and BAT depots are completely differ-
ent and brown adipocytes appear to be closer to myocytes than to white
adipocytes (Figure 1.5).
Figure 1.5: Pathways to the development of white and brown adipocytes.
Modified from Cristancho et al. [41].
Novel findings have refuted this hypothesis [42] and led to the formu-
lation of two different models for Myf5+ cells contribution to the develop-
ment of adipocytes. According to the first model, proposed in [42], Myf5+
(and possibly Pax3+) cells are spatially mixed with Myf5– precursors in the
same depots. The relative abundance of the two cell types is a function of
the depot itself. For instance, in murine BAT depots will preveal Myf5+
progenitors and in inguinal WAT the Myf5– lineage will be the most abun-
dant. In other WAT depots, like subcutaneous one, the two populations
16
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are more equally distributed. Despite this heterogeneity, the recruitment
of adipocyte progenitors is quite selective: while in BAT and subcutaneous
WAT the Myf5+ will differentiate into mature adipocytes, in inguinal WAT
the Myf5– is favored. The second model described in [42] proposes that the
expression of Myf5 and Pax3 might occur later in time, during recruitment
or differentiation, hence the majority of adipogenic precursors in different
depots should be Myf5– [2].
The recruited brown preadipocytes differentiate into mature fat cells
with a transduction cascade mostly similar to that previously described
for WAT. PPARγ remains the key transcription factor of adipogenesis, but
C/EBPα is not as fundamental as it is in white adipocytes [43]. Never-
theless, PPARγ function is supported by important brown-specific factors
during adipogenesis, which are PPARγcoactivator 1α (PGC-1α) and PRD1-
BF-1-RIZ1 homologous domain containing protein 16 (PRDM16). PGC-1α
has a crucial role in the development of mature brown adipocytes, as it
positively induces mitochondrial biogenesis and oxidative metabolism and
upregulates many thermogenic genes, including UCP1 [44]. Despite its
role in promoting thermogenesis, the ablation of PGC-1α has no effect on
total BAT mass [43]. PRDM16 is a key determinant of brown fat fate.
When expressed in preadipocytes and myoblasts, it can induce a complete
brown adipose phenotype [45]. Its effects are achieved by the physical in-
teraction with several DNA-binding factors (including PPARs, PGC-1α and
C/EBPs), rather than the direct interaction with DNA [45]. Its depletion
from brown preadipocytes induces the emergence of a muscular phenotype
[46]. The differentiation of novel brown adipocytes is timed by the induc-
tion of PRDM16: despite its regulatory pathway is mostly unknown, BMPs
have been recently found to be involved in this regulation. The most critical
member seems to be BMP7, which can induce PRDM16 enhancing brown,
but not white, adipogenesis [47].
17
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1.3 Thermogenesis
As mentioned above, thermogenesis is the physiological process that
enables brown adipocytes to produce heat instead of ATP following the
catabolism of high energy substrates. It is also called non-shivering ther-
mogenesis because the spastic contraction of subcutaneous muscles is not
involved in heat generation [33].
The so-called cold-induced thermogenesis is the response of the body to
a decrease in external temperature and is triggered by the hypothalamus
(Figure 1.6) to counterbalance the loss of energy induced by the variation
in the thermal condition [48]. The perception of a modification in external
temperature is sensed by thermal sensory receptors on skin, which trans-
mit a signal to primary sensory neurons in dorsal root ganglia, which in
turn transfer the information to the dorsal horn. A glutamatergic signal is
sent to subnuclei of the lateral parabrachial nucleus and then to the preop-
tic area of the hypothalamus. Here, a stimulatory response activates W-S
neurons in the dorsomedial hypothalamus which in turn stimulate BAT
sympathetic premotor neurons in rostral raphe pallidus. This signal prop-
agates to BAT sympathetic preganglionic neurons in the intermediolateral
nucleus, activating the peripheral release of norepinephrine (NE) in BAT
nerve ends [49].
The brown adipocyte expresses membrane β3-adrenoreceptors (β3-ARs)
activated by the NE surge caused by cold exposure. The entity of heat
production depends on the level of sympathetic activation, the quantity of
released NE and the amount of NE efficiently binding β3-ARs [50]. The ac-
tivated β3-ARs stimulate the production of cyclic adenosine monophosphate
(cAMP) by the enzyme adenylyl cyclase (AC) via the activity of associated
stimulatory G protein. The elevated cAMP intracellular level is important
for the activation of protein kinase A (PKA), a key enzyme with multi-
ple targets involved in the activation of thermogenesis [51]. PKA phos-
phorylates the cAMP response element-binding (CREB) transcription fac-
18
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Figure 1.6: Central pathway leading to sympathetic activation and NE release
in mice. POAH: preoptic chiasma/anterior hypothalamus; GABA:
γ-aminobutyric acid; VMN: ventromedial nucleus; c: unidentified
stimulus converter; aq; aquaduct; glu: glutamate; RR: retrorubral
field; IML: intermediolateral neurons; ACh: acetylcholine; NE:
norepinephrine; NPY: neuropepdite Y. From Cannon & Nedergaard
[33].
tor, which upregulates several genes, including UCP1 [52] and activates
the p38 mitogen-activated protein kinase (MAPK) signaling cascade. p38
MAPK has a key role in phosphorylating the activated transcription factor
2 (ATF2) and PGC-1α, which in turn positively regulate the expression of
UCP1 [53]. Moreover, ATF2 also upregulates PGC-1α expression. More-
over, PKA activation promotes lipolytic pathways in brown adipocytes.
1.3.1 The role of lipolysis in thermogenesis
Thermogenesis and lipolysis are two intimately related processes. In-
deed, thermogenesis cannot occur without the onset of lipolysis, besides
lipolysis itself represents a sufficient event to activate thermogenesis [33].
In brown adipocytes, lipolysis is mediated by adrenergic stimulation and
cAMP-mediated PKA activation. The central event is the phosphoryla-
tion of hormone-sensitive lipase (HSL) and of perilipins. Perilipin (PLIN)
is a family of proteins found in the phospholipid monolayer that envelops
LDs. Among different types, PLIN1 and PLIN5 are present in fat-storing,
19
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grown LDs and have the most prominent protective role, while others are
mostly expressed in growing LDs [54]. The PKA-mediated phosphoryla-
tion of Ser660 in HSL translocates the enzyme from the cytosol to the LD
[55]. Hyperphosphorylation of PLIN1, which is supported by optic atrophy
1 (OPA1) [56], inactivates its protective funtion and exposes TAGs to active
lipases, which release glycerol and FAs [54].
The products of lipolysis are then intercepted by fatty acid binding pro-
tein 4 (FABP4) and chaperoned towards mitochondria [57]. Like in any
other cell, FAs enter mitochondria via the carnithine palmitoyltransferase
(CPI) proteins and undergo canonical steps of β-oxidation and the result-
ing acetyl-CoA enters the citric acid cycle. Another possible fate for FAs in
mitochondria is the direct activation of UCP1 [33].
1.3.2 Regulation of UCP1 expression and thermogene-
sis
The activation of thermogenesis and, consequently, the expression of
UCP1 are NE-dependent. The transcriptional regulation of UCP1 is com-
mitted by the 5’ non-coding region of UCP1 gene, which shares sequence
homology in humans and rodents [58]. This portion of the gene contains a
proximal regulatory region, which is immediately before the transcription
initiation site, containing a number of transcription factor binding site. The
distal enhancer is another important regulatory site, as it promotes UCP1
expression when interacts with activated nuclear receptors.
Positive regulation
The proximal regulatory region contains the cAMP response element
(CRE), targeted by the active CREB, whose phosphorylation is under direct
control of cAMP [59]. The zinc finger protein 516 (Zfp516) has been recently
described as a cold-induced transcription factor which can directly bind to
the proximal regulatory region of UCP1 promoter to increase its expres-
20
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sion. The interaction involves the physical association with PRDM16 [60].
Other important regulatory sites present in this region are the elements
that interact with C/EBPα and β, previously described as pro-adipogenic
factors, which bind to the promoter following the physical interaction with
PRDM16 [45, 61].
The distal enhancer of UCP1 promoter contains another CRE and many
sites targeted by hormone- and nuclear receptors-mediated transcription
factors. PPARα and PPARγ directly interact with UCP1 enhancer to pro-
mote its expression while forming a heterodimer with retinoid X receptors
(RXRs) [62]. Unlike PPARγ, PPARα is selectively expressed in BAT and
promotes thermogenic activity, as many of its target genes are oxidative
enzymes [62].
Isomers of retinoic acid can promote UCP1 synthesis binding to differ-
ent nuclear receptors. Specifically, all-trans retinoic acid (atRA) binds to
retinoic acid receptors (RARs), while cis-9 retinoic acid (c9RA) binds to both
RAR and RXRs. Activated retinoid receptors directly promote UCP1: RXRs
forms heterodimers with RARs and PPARs that interact with the distal en-
hancer [63].
Also hormone-mediated regulation of UCP1 expression occurs through
the distal enhancer. Thyroid hormones triiodothyronine (T3) and thyrox-
ine (T4) are involved in the upregulation of UCP1 thanks to the interaction
of T3 with the nuclear thyroid receptor (TR), which directly binds to its
responsive element on the enhancer [64]. T4 indirectly promotes gene ex-
pression because it is converted to active T3 by the type II iodothyronine
5’-deiodinase (DIO2) prior to the bond with its receptor [65]. Estrogens
participate in UCP1 expression because activated estrogen-related recep-
tors (ERRs) α, β and γ can bind to an ERR responsive element in distal en-
hancer; moreover, a number of pro-thermogenic actions have been recently
described for estrogen in brown and white adipocytes [66].
21
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Negative regulation
Receptor interacting protein 140 (RIP140) is a repressor that alters
thermogenesis by inhibiting PGC-1α activity, inducing a downregulation of
downstream genes (i.e. PPARG, PPARA and ERRA) and decreasing UCP1
expression [67].
The liver X receptor α (LXRα) directly inhibits UCP1 transcription by
forming a complex with RIP140 that ablates PPARγ from the gene pro-
moter [68].
The activated receptor for vitamin D also acts as a repressor of UCP1
and thermogenesis, but its mechanism of action is still matter of debate
[69].
The retinoblastoma protein (pRb) is a tumor-suppressing protein with a
key role in differentiating preadipocytes into white adipocytes and acts as
a thermogenic repressor by inhibiting the expression of PGC1A gene [70]
and hindering PPARγ activity [71].
The twist basic helix-loop-helix transcription factor 1 (Twist1) is a neg-
ative regulator of thermogenesis induced by PPARδ which inhibits PGC-1α
at a transcriptional level [72].
The two members of steroid receptor coactivator (SRC) family SRC2 and
SRC3 negatively regulate thermogenesis by acting on PGC-1α through dif-
ferent mechanisms [68]. In particular, SRC2 blocks the interaction between
PPARγ and PGC-1α, thus the expression of UCP1 is reduced [73]. Con-
versely, SRC3 impairs the transcriptional activity of PGC-1α by recruiting
an acetyltransferase which inactivates PGC-1αby its acetylation [74].
The transient receptor potential cation channel subfamily V member
4 (TRPV4), also known as vanilloid-receptor related osmotically activated
channel, is a membrane ion channel. Its activation by endogenous or ex-
ogenous agonists triggers a Ca2+ influx that, via ERK 1/2 pathway, in-
hibits PGC-1α expression and its downstream thermogenic targets [75].
Moreover, TRPV4 activation promotes the production of proinflammatory
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chemokines that favor the onset of insulin resistance [75].
1.3.3 The function of UCP1
UCP1 is located in the inner mitochondrial membrane and belongs to
the SLC25 family of mitochondrial solute carriers [76]. Its role in thermo-
genesis is to uncouple the oxidative phosphorylation from the synthesis of
ATP. To do this, UCP1 breaks the proton gradient existing in mitochon-
dria inducing a leakage of H+ in the intermembrane space; in this way, the
electrochemical gradient is converted into heat and cannot fuel ATP syn-
thesis [77]. When brown adipocytes are inactive, UCP1 does not perform
thermogenesis because either exposed to the inhibitory action of purine
nucleotides or lacks of activating cofactors, i.e. FAs [33]. In fact, UCP1
activity is positively regulated by FAs and negatively regulated by purine
nucleotides. The way FAs activate UCP1 is still matter of debate [33, 77],
as high UCP1 activity has been observed also in absence of stimulatory
FAs [78]. The models proposed for FA-induced UCP1 activation have been
reviewed by Cannon and Nedergaard [33].
1.4 Recruitable thermogenic adipocytes
The canonical classification of AT into WAT and BAT became too sim-
plistic in recent years, as it has been observed that populations of thermo-
genic adipocytes may appear into WAT depots. They were first identified by
Lazar in 2008 [79] and extensively described in both mouse and human in
2012 by Wu and colleagues [80]. These inducible fat cells were named beige
or brite (brown-in-white) adipocytes. These cells are recruitable from white
adipocytes that may acquire the thermogenic ability after proper stimu-
lation. The conversion of white adipocytes into beige/brite cells is called
browning (Figure 1.7).
The most powerful browning stimulus is the sympathetic response to
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Figure 1.7: Conversion of white adipocytes to brown adipocytes. LV: lipid
vacuole; M: mitochondrion; N: nucleus. Modified from Ro et al. [81].
cold exposure which, as described for BAT, triggers a peripheral release of
NE also in WAT depots [82], despite their lower innervation in comparison
to BAT ones [83]. Also in white adipocytes, the surge of NE activates β3-ARs
which, through the signaling cascade already described for brown fat cells,
stimulate the expression of UCP1 and other thermogenic genes. Therefore,
PGC-1α synthesis is increased and mitochondrial biogenesis is enhanced.
These changes are flanked by a dynamic remodeling of lipid stores, as the
big LD that characterizes white adipocytes is fragmented into multiple,
smaller LDs and lipolysis is empowered.
WAT depots do not respond to cold exposure with the same extent,
as acute cold exposure induces a rapid response mainly in inguinal and
retroperitoneal depots. Visceral and perigonadal depots are less prone to
recruit brite adipocytes and they need a chronic exposure to induce brown-
ing [4]. The response of mature white adipocytes to cold exposure depends
also on the proximity to noradrenergic sympathetic nerve ends, depot vas-
cularization and the exposure to favorable micro-environmental conditions.
When the browning stimulation ceases, brite adipocytes acquire a typical
white phenotype; this does not occur in canonical brown adipocytes, as even
when they are inactive their phenotypic characteristics and molecular sig-
nature do not change.
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1.4.1 Origin of brite adipocytes
Browning of white adipocytes is not the only way to recruit brite cells in
WAT depots. Indeed, brite adipocytes may arise from precursors not shared
with white adipocytes. WAT browning and differentiation of de novo brite
adipocytes coexist with depot-specific differences [2]. Since brite adipocytes
are recruited in WAT depots, their precursors should be Myf5–. Actually,
they can be either Myf5+ or Myf5–, according to the anatomical fat pad from
which they originate.
A recent study showed that adipose progenitors PDGFRα+, Sca-1+ and
CD34+ in murine abdominal fat depots can differentiate into both white
and brite adipocytes following a moderate β3-adrenergic activation [21]. It
has also been demonstrated that brite cell precursors may lack a number
of surface markers present in the precursors of other adipocytes [2].
It is now ascertained that PDGFRα+ adipose progenitors can differenti-
ate into white or brite adipocytes regardless of Myf5 expression. The two
phenotypes are interchangeable according to the degree of sympathetic ac-
tivation without any impact on the expression of surface markers [2].
1.4.2 Molecular signature of brite adipocytes
The first studies on brite adipocytes demonstrated that these cells have
comparable expression profiles with both brown and white adipocytes. How-
ever, these cells also express a spectrum of brite-specific genes that can be
treated as distinctive markers. The first genes recognized as selective brite
markers were the developmental transcription factor TBX1, the transmem-
brane protein TMEM26 and the tumor necrosis factor receptor superfamily
member CD137 [80]. Their expression was elevated in inguinal subcuta-
neous WAT of mice [80], which is a notable source of recruitable thermo-
genic adipocytes. Nonetheless, in vivo β3-adrenergic activation of murine
inguinal white adipocytes did not evoke an increase of Tbx1 and Tmem26
expression, while other putative surface markers were selectively upregu-
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lated [84]. These genes, namely Pat2 and P2rx5, were selectively upregu-
lated in brown and brite adipocytes, with Pat2 being more close to brite
adipocyte markers [84]. Notably, the markers characterized in this re-
search partly or totally lost their discriminating ability when isolated prea-
dipocytes were immortalized and differentiated into mature fat cells. This
study also pointed neuregulin 4 (NRG4) as an adipose-specific potential
marker, despite no differences were found between white and brown adi-
pocytes [84]. Later research stated that actually the specificity for NRG4
expression exists for brite adipocytes and the gene has been proposed as a
brite marker both in mice [85] and in humans [86].
A massive up-regulation of Tbx1 was demonstrated in recruited murine
thermogenic cells, while Tmem26 was induced just in SVF [87].
Primary murine adipocytes treated with rosiglitazone, a PPARγ agonist,
became brite and exhibited an upregulation of canonical thermogenic genes
and putative brite markers, with the exception of Tmem26 [88]. Adrener-
gic stimulation of these brite adipocytes lowered the expression of some
markers, including Tbx1 and P2rx5, which lost their discriminating abil-
ity compared to control white adipocytes. The characterization of SVF
adipocyte precursors demonstrated the highest levels of specific markers
(TBX1 and TMEM26) compared to mature adipocytes [88]. Taken together,
these results show that the accuracy of putative brite markers depends on
many factors. For instance, in vivo and in vitro models differently express
TBX1 and CD137 [88]. In vivo, CD137 does not meet the marker criteria
because its levels are regulated by other physiological processes different
from browning [89]. Moreover, immortalized cell lines might lose the ex-
pression of some biomarkers [84, 88], and in vitro adrenergic stimulation
might downregulate the expression of a number of biomarkers [88]. In
light of these findings, unambiguous validated brite biomarkers are lim-
ited to fibroblast growth factor 21 (FGF21), carbonic anhydrase 4 (CAH4)
and Cbp/P300-interacting transactivator 1 (CITED1), even if the last one
is negatively affected by adrenergic activation [88].
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1.4.3 Dynamic of LD remodeling during browning
Lipid droplets are organelles with a dynamic nature, since they undergo
several important changes during cell life and in response to metabolic
variations. LDs are organelles generated via the endoplasmic reticulum
(ER) through a seipin-mediated complex machinery that allows intralumi-
nal lipid synthesis and budding from the ER membrane of the nascent LD
[90, 91]. Cytoplasmic LDs are packed within a phospholipid monolayer
that includes a mosaic of LD membrane-associated proteins [90].
The enlargement of LDs in differentiating adipocytes occurs via de novo
lipogenesis and LD fusion. This process takes place when two LDs begin
a mutual contact and the smaller droplet transfers its lipid content in the
larger one [91]. In the contact site between two fusing LDs, a trans homod-
imer between cell death-inducing DNA fragmentation factor alpha-like ef-
fector A (CIDEA) and CIDEC (also known as fat-specific protein 27, FSP27)
is formed. The protein complex forms a channel through which lipids are
slowly transferred to the large LD, driven by a pressure gradient [91].
LD-associated proteins are differentially expressed among different fat
depots. A study demonstrated that most LD-associated proteins are par-
ticularly enriched in murine interscapular BAT [92]. Interestingly, CIDEA
has been found overexpressed only in BAT, while different WAT depots ex-
press only CIDEC; this is true in mouse [93], since human WAT expresses
CIDEA as well [94]. This finding has led the use of CIDEA as a selec-
tive BAT marker in mouse experiments and pointed out a different role of
CIDEA and CIDEC in LD remodeling. CIDEA is a mediator of LD fusion,
as stated above, but CIDEA alone cannot achieve an unilocular phenotype,
typical of WAT [95]. To obtain large LDs as in white adipocytes, CIDEC’s
activity is compulsory. Its lipid transfer efficiency can be improved by the
interaction with PLIN1, despite this is not strictly necessary to achieve the
unilocular phenotype [96]. This explains why, at least in mouse, Cidea ex-
pression is limited to BAT and Fsp27 is conversely more expressed in WAT.
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Recently, a differential role for FSP27 in BAT and WAT has been de-
scribed in mouse. A new isoform of FSP27, alternatively transcribed by
the same gene, has been found in liver and BAT. This isoform, known as
FSP27β, is synthesized through the activation of a different promoter [97].
The native form, namely FSP27α, is expressed in white adipocytes and
dimerizes to promote LD fusion towards the unilocular phenotype. The
role of FSP27β is not clear. Nevertheless, a model for its function in LD dy-
namic has been proposed. The interaction of FSP27β with CIDEA should
prevent the formation of the heterodimer that promotes LD fusion. In this
way, fusion is prevented and LDs maintain a small size [94].
In human, both CIDEA and CIDEC are expressed in all types of AT and
their expression level is positively correlated with insulin sensitivity [98].
They are supposed to have a beneficial role, since they are overexpressed
to reduce ectopic accumulation of fat, storing it in adipocytes, and thus to
improve insulin sensitivity [94].
When browning occurs, a change in LD morphology can be appreciated
[92, 99]. A significant β3-adrenergic activation in white adipocytes switches
the unilocular phenotype to a multilocular one. Stimulated cells decrease
the dimensions of their LDs due to the NE-dependent activation of lipoly-
sis. Concurrently, de novo lipid synthesis is also stimulated: existing LDs
become surrounded by a multitude of micro LDs which are enlarged as
a consequence of lipogenesis and CIDE’s activity [92]. This physiological
response is achieved to improve the efficiency of lipolysis: smaller LDs in-
crease the total surface accessible to lipases, so a higher mass of TAGs
is oxidized to fuel mitochondrial thermogenesis [92, 99]. The adrenergic
stimulus can also trigger energy-consuming metabolic pathways, included
a lipolysis/lipogenesis futile cycle involved in LD remodeling and reducing
lipid content in a UCP1-independent way [100].
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1.4.4 Mitochondrial dynamics during browning
Mitochondria are also dynamic organelles in cells, as they undergo con-
tinuous episodes of fusion and fission. Fusion produces complex and highly
interconnected mitochondrial networks composed by elongated, tubular mi-
tochondria. These interconnected mitochondrial networks are important
for communication between organelles and transfer of mitochondrial DNA
gene products [101]. The elongated mitochondrial shape is associated with
highly energy demanding conditions, as tubular mitochondria are more ef-
ficient in ATP synthesis [102]. For instance, interconnected mitochondrial
networks have been observed in white pre-adipocytes at the beginning of
their differentiation into mature cells [99].
During mitochondrial fission, the elongated networks splinter into dis-
crete, circular mitochondria which eventually can show swelling. Fissed
mitochondria can be more easily distributed in the cytoplasm [101]. De-
spite fission has been frequently associated with apoptosis [103], it has a
precise physiological meaning in thermogenic adipocytes. Mitochondrial
fission has been proven to be associated with low energy demanding sit-
uations, like thermogenesis [103], in which the catabolism of high energy
substrates does not fuel the production of ATP.
The molecular machinery driving fusion and fission involves the activ-
ity of dynamin-related proteins (DRPs), which can remodel mitochondrial
membranes thanks to their GTPasic activity [101]. Fusion is mediated by
two sets of proteins: mitofusins (MFN) 1 and 2 join together the outer mem-
branes of mitochondria, while the fusion of inner membranes is achieved
by OPA1, which also maintains the architecture of cristae [104]. Little is
known about factors regulating mitochondrial fission. DRP1 is, thus far,
the only described protein involved in fission [104].
In brown adipocytes, fission is stimulated by β3-adrenergic activation,
thus it is narrowly coupled with thermogenesis. NE has a role in stim-
ulating fission by activating PKA, which in turn phosphorylates DRP1,
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turning it in an active form [103]. Fission produces small globular mito-
chondria. Once the thermogenic stimulus ceases, the mitochondrial archi-
tecture returns to an elongated, interconnected web of tubular mitochon-
dria [103]. NE favors mitochondrial fission by enhancing DRP1 activity
in a PKA-dependent way and prevents mitochondrial fusion by abrogating
mitochondria-bound OPA1 [105]. OPA1 inhibition also provokes mitochon-
drial swelling [106]. NE-induced fission is functional for energy expen-
diture, because fragmented mitochondria surrounding LDs become more
sensitive to FAs. As a consequence, UCP1 activation is improved and mito-
chondria oxidize FAs more efficiently [103].
This physiological model occurs also during browning, as the NE-driven
mitochondrial biogenesis is flanked by DRP1-mediated fission and remod-
eling of LDs. The difference in mitochondrial architecture between brown
and brite adipocytes lies in the behavior of the cells after the ending of
the thermogenic stimulus. Unstimulated brown adipocytes fuse their mi-
tochondria into native interconnected webs [103] and, moreover, maintain
a constitutively high level of mitochondrial biogenesis [107]. Unstimulated
brite adipocytes come back to a white phenotype in a process that involves
both the decline of mitochondrial biogenesis and the stimulation of mi-
tophagy, i.e. the controlled disruption of mitochondria [107]. Mitophagy is
activated when mitochondria lose their membrane potential and recruit the
parkin protein [108]. The proton leakage promoted by UCP1 prevents mi-
tophagy and parkin is strongly repressed by β3-adrenergic activation. The




Browning as a therapeutic
strategy
The physiological changes induced in WAT by browning opened new
perspectives in adipobiology and obesity research. In particular, there is
growing interest in the induction of WAT browning in obese patients as a
therapy for obesity and related co-morbidities.
2.1 An overview on obesity
Obesity is a complex disease in which excess energy is accumulated.
The BMI is the parameter of choice to discriminate between normal weight,
overweight and obese individuals: people with a BMI between 25 and 30 kg
m–2 are overweight, while individuals with a BMI that exceeds 30 kg m–2
are obese [109]. Nevertheless, this parameter does not take into account
the dishomogeneous distribution of fat mass across different depots. The
severity of obesity depends on the degree of fat accumulation in different
depots [110]. An excess of fat in the upper part of the body (i.e. abdomi-
nal obesity) is a typical feature of obese men and is highly correlated with
diabetes and cardiovascular disease. Conversely, when fat mostly accumu-
lates in the lower part of the body (mostly in the gluteo-femoral depot),
the correlation with severe morbidities is much lower. This phenotype is
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widespread among obese women.
Obesity has gained a worldwide epidemic distribution, with nearly one
billion of individuals being obese [109]. The treatment of obesity becomes
then a primary concern in global health, but the traditional approaches (i.e.
modification of dietary habits, physical exercise) are not always effective,
since the regain of fat mass is a likely feature [111]. Bariatric surgery is
an interesting alternative, but is not available in all cases [109]. In this
scenario, WAT browning is claimed as a promising alternative therapeutic
tool.
2.2 Therapeutic significance of browning
The interest of the scientific community about WAT browning derives
from the high metabolic capacity of BAT in dissipating energy as heat.
Being highly vascularized and innervated, BAT can respond promptly to
thermogenic stimuli and mobilize energy substrates to be oxidized. This
interest further grew after the discovery of functional BAT in adult hu-
mans and of brite adipocytes enclosed in WAT depots [112]. The activation
of thermogenesis in brown and brite fat cells should lead to the depletion
of cellular lipid stores. Consequently, a flow of glucose and FAs should be
mobilized towards these cells to fuel the thermogenic machinery, leading
to a decrease of ectopic fat depots and an increase in AT insulin sensitivity
[112].
Unlike rodents, BAT in adult humans represents only 2.7% of total body
weight (5.5% in women, 1.3% in men) and its content is inversely correlated
to BMI [113]. PET-CT measurements and mathematical models estimated
that mass and volume of functional BAT in adult humans are respectively
50 g and 137 cm3 [114]. In terms of metabolic contribution, adaptive ther-
mogenesis in thermoneutral conditions represents 5% of basal metabolic
rate (BMR) [114]. A 4% increase of BMR through adaptive thermogen-
esis, with the contribution of recruited brite adipocytes, could produce a
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3% reduction of total body weight per year, assuming that the activation
is chronically sustained [115]. This can be true if functional tolerance is
avoided [116] and if thermogenesis is not impaired and compensated by an
increase in food assumption [117].
The administration of the β3-adrenergic agonist mirabegron caused a
13% increase in BMR [118]; if chronically sustained, this activation could
induce an 8% decrease in total body weight per year. It has to be stressed
that the chronic thermogenic activation induced by exogenous substances
has been only assumed in the cited researches and it deserves further elu-
cidation [112].
These results assume that brite adipocytes contribute to metabolic rate
to the same extent of brown fat cells, although a basal thermogenesis in
BAT in absence of thermal challenges may occur [119]. Moreover, there is
growing evidence that thermogenesis in brite adipocytes can occur through
alternative processes that do not involve UCP1 expression, like the futile
lipolysis and lipogenesis cycle [100, 120]. Taken together, all these state-
ments show a complex panorama that still needs deeper understanding to
translate the results of scientific research about adipobiology and physiol-
ogy of browning into routinary clinical practice.
2.3 Inducing WAT browning
The activation of BAT and the recruitment of brite adipocytes, in terms
of UCP1 expression and modifications of intracellular architecture as de-
scribed above, can occur through a number of different pathways involving
a number of signaling cascades and transcription factors. The main molec-
ular hallmark is β3-AR, which responds to NE surges following thermal
challenges. Cold exposure is the most effective way to activate thermogen-
esis in AT [121].
Other endogenous mechanisms can produce browning. These processes
can be driven by hormonal compounds or by other molecular mediators
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acting directly on UCP1 promoter or on upstream transcription factors.
Some of these molecules are centrally active and can activate sympathetic
nervous system to produce a peripheral release of NE. Among endogenous
factors, myokines produced by contracting skeletal muscles are gaining in-
terest because their browning activity could strengthen the existing link
between weight loss and physical exercise. For instance, studies on the
browning activity of β-aminoisobutyric acid [122] and brain-derived neuro-
trophic factor [123] have been performed with interesting results, but fur-
ther characterization is needed, since their molecular mechanisms and the
effect on LD and mitochondrial dynamics are mostly unknown. A plethora
of such endogenous browning factor have been reviewed in [109, 124].
Browning can be also induced by external molecules. Historically, a
number of anti-obesity drugs were present; many of them have been with-
drawn because of their deleterious side effects [112]. Nevertheless, studies
about different pharmacological molecules have shown interesting brown-
ing effects, despite their primary target is not AT, like selective serotonin
re-uptake inhibitors and tamoxifen [109]. Concerning exogenous molecu-
les, the attention is now focused on the study of bioactive compounds found
in nature (e.g. nutraceuticals from plants). Among these, capsaicin can
induce WAT browning by directly activating adipocyte transcriptional pro-
gram and by triggering a central stimulation that ends up in the periph-
eral release of NE. Despite the molecular pathway activated by capsaicin
has been characterized [125, 126], little is known about long term effects
of capsaicin administration and its effects on structural variations. The β-
carotene-derived retinoic acid is another bioactive compound with brown-
ing activity, but only the effect of the all-trans isomer has been extensively
described [63], as its cis-9 isomer has not been fully characterized yet. A
high number of bioactive molecules deserves deeper studies to better ex-
ploit the way they can induce browning and to which extent.
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Aim of the thesis
This thesis aims to gain new insight about the principal features of
WAT browning. The effects of chosen bioactive compounds on cells was
evidenced in terms of gene expression and modifications of the structure of
lipid droplets and mitochondria. The attention was focused on delineating
the browning effect of selected endogenous and nutraceutical molecules,
such as β-aminoisobutyric acid, capsaicin, brain-derived neurotrophic fac-
tor and cis-9 retinoic acid, on white and brite preadipocytes and differen-
tiated adipocytes. Simpson-Golabi-Behmel syndrome cell strain, a human
model of white preadipocytes, was also investigated in order to characterize






Chemicals and culture media
The chemicals and culture media used in the experiments presented
in this thesis, together with the buffers and solvents, have been listed in
Table 4.1. Kits and chemicals for RNA extraction, cDNA synthesis and
amplification were listed in Table 4.2, together with products and dyes used
in structural analyses, immunofluorescence and in-cell Western.
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Table 4.1: Reagents and media for cell cultures and for buffer preparation.
DMEM/F12: Dulbecco’s modified Eagle medium/Ham’s F12; HEPES:
4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid.
Cell culture media and reagents
Product Identifier Source
DMEM/F12 (1:1) 31330038 Thermo Fisher Scientific
High glucose DMEM, GlutaMAX™ sup-
plement
10566016 Thermo Fisher Scientific
Biotin B4639 Sigma-Aldrich
D-pantothenic acid hemicalcium salt P5155 Sigma Aldrich
Penicillin-streptomycin 15140122 Thermo Fisher Scientific
Amphotericin B 15290026 Thermo Fisher Scientific
Fetal bovine serum 10270106 Thermo Fisher Scientific
Human apo-Transferrin T2252 Sigma-Aldrich
Human insulin I1507 Sigma-Aldrich
Hydrocortisone H0888 Sigma-Aldrich
3,3’,5-Triiodo-L-thyronine sodium salt T6397 Sigma-Aldrich
Dexamethasone D1756 Sigma-Aldrich
3-Isobutyl-1-methylxanthine I5879 Sigma-Aldrich
Rosiglitazone 71740 Cayman Chemical
Indomethacin 70270 Cayman Chemical
3-Aminoisobutyric acid AG-CR1-3596 AdipoGen Life Sciences
Capsaicin 92350 Cayman Chemical
Brain-derived neurotrophic factor 4004 BioVision Inc.
9-cis-Retinoic acid 14587 Cayman Chemical
L-(–)-norepinephrine bitartrate hydrate 16673 Cayman Chemical
(–)-Isoproterenol hydrochloride I6504 Sigma-Aldrich
Thiazolyl blue tetrazolium bromide (MTT) M5655 Sigma-Aldrich
Oil red O solution O1391 Sigma-Aldrich
Salts, buffers and solvents
Sodium chloride S7653 Sigma-Aldrich
Potassium chloride P9333 Sigma-Aldrich
Sodium phosphate dibasic S7907 Sigma-Aldrich
Potassium phosphate monobasic P5655 Sigma-Aldrich
Hank’s balanced salt solution ECM0507L Euroclone S.p.A.
HEPES buffer ECM0180D Euroclone S.p.A.
TWEEN® 20 P7949 Sigma-Aldrich
Absolute ethanol 3086052 Carlo Erba Reagents S.r.l.
2-Propanol I9516 Sigma-Aldrich
Dimethyl sulphoxide D2650 Sigma-Aldrich
Buffered neutral 10% formalin 05-01004F Bio-Optica S.p.A.
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Table 4.2: Reagents and kits for molecular biology protocols, structural analyses,
immunofluorescence and in-cell Western. TBE: tris/borate/EDTA;
DAPI: 4’,6-diamidino-2-phenylindole.
Products for molecular biology
Product Identifier Source
TRIzol™ reagent 15596026 Thermo Fisher Scientific
Chloroform C2432 Sigma-Aldrich
PureLink™ RNA Mini Kit 12183018A Thermo Fisher Scientific
SuperScript™ III one-step RT-PCR system 12574026 Thermo Fisher Scientific
Agarose EMR010001 Euroclone S.p.A.
GelRed® 41003 Biotium
1 kb DNA ladder 31022 Biotium
TBE AM9863 Thermo Fisher Scientific
ImProm-II™ Reverse Transcription System A3800 Promega Corporation
Transcriptor High Fidelity cDNA Synthesis
Kit
5091284001 Roche Diagnostics
Platinum™ SYBR™ Green qPCR
SuperMix-UDG
11733046 Thermo Fisher Scientific
Fluorescent dyes
BODIPY™ 493/503 D3922 Thermo Fisher Scientific
MitoTracker™ Orange CMTMRos M7510 Thermo Fisher Scientific
Fluo-8 AM ab142773 Abcam
Protein expression reagents
Triton™ X-100 T9284 Sigma-Aldrich
Glycine G8898 Sigma-Aldrich
Ammonium chloride A9434 Sigma-Aldrich
Normal goat S-1000 Vector Laboratories
Bovine serum albumin fraction V 10738328103 Roche Diagnostics
Anti-rabbit AlexaFluor® 555 ab150078 Abcam
Anti-rabbit fluorescein IgG FI-1000 Vector Laboratories
Anti-mouse fluorescein IgM FI-2020 Vector Laboratories
Anti-rabbit IRDye® 800CW 925-32211 LI-COR Inc.





5.1 Establishing culture media formulation
The experiments presented in this doctoral thesis have been performed
on different adipose cell lines: Simpson-Golabi-Behmel syndrome (SGBS)
human preadipocytes, 3T3-L1 murine preadipocytes and X9 murine prea-
dipocytes. These cells need different formulations to achieve satisfactory
growth and differentiation rate, but they show common features in the cul-
ture protocol.
After thawing, cells are plated on culture dishes or microscopy slides
and are cultured in a growth medium to reach a confluence rate close to
or equal to 100%. The exact time each cell type requires for clonal expan-
sion varies according to: i) seeding density; ii) desired confluence rate; iii)
cell viability. In general, for all cell types used, clonal expansion from the
seeding day to reach 90% confluence requires 5-8 days, starting from 5,000
cells/cm2.
When cells reached a satisfactory confluence rate, differentiation has
been induced with differently formulated differentiation media according
to cell type. The differentiation medium formulation is critical for the
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successful achievement of cell differentiation, hence this aspect has been
carefully studied and different formulations have been tested to find the
optimal differentiation conditions.
The incubation with differentiation medium normally lasted from 2 to 4
days and was followed by the administration of the maintenance medium,
which is formulated in a way that keeps cells in their differentiated state,
allowing fat accumulation in their LDs until they become fully differen-
tiated adipocytes. The administration of the maintenance medium lasts
until cell sampling for analyses and its formulation depends on the differ-
entiation medium, so different formulation have been tested accordingly.
For all the experiments reported in this doctoral thesis, cells were grown
in a Forma™ Steri-Cycle™ i160 CO2 incubator (51030301 Thermo Fisher
Scientific) at 37°C, with 5% CO2 and 95% relative humidity.
5.1.1 SGBS cells
A stock of SGBS human preadipocytes has been kindly provided by prof.
Martin Wabitsch (University of Ulm). The culture media formulation for
SGBS cells has been described by Wabitsch and colleagues, who first iso-
lated this model and implemented their in vitro growth [127]. The sug-
gested media formulation has been reported in Table 5.1.
The media presented in Tabel 5.1 achieved satisfactory results in terms
of cell expansion and differentiation. Nevertheless, we observed a signif-
icant decline in LD formation in SGBS cultures at high passage number.
For this reason, being hydrocortisone recognized as a powerful lipogenic
and antilipolitic factor [128], the differentiation and maintenance media
have been reinforced with additional 150 nM hydrocortisone, to a final con-
centration of 250 nM. The duration of cell incubation with differentiation
and maintenance media did not change from how suggested by Wabitsch
and colleagues [127]: after two washes with phosphate buffer saline (PBS)
1X, 90% confluent cells were incubated with the differentiation medium for
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4 days. The incubation with maintenance medium, refreshed every 4 days,
lasted until cell sampling. This growth protocol has been adopted in the
results presented in Chapter 11.
Table 5.1: Formulation of SGBS cells culture media as reported by Wabitsch et
al. [127]. DMEM/F12: Dulbecco’s modified Eagle medium/Ham’s F12;
FBS: fetal bovine serum; P/S: penicillin/streptomycin; IBMX:
isobutylmethylxanthine.
Reagent Growth Differentiation Maintenance
medium medium medium
Basal medium DMEM/F12 DMEM/F12 DMEM/F12
FBS 10% – –
P/S 1% 1% 1%
Biotin 33 µM 33 µM 33 µM
Panthotenic acid 17 µM 17 µM 17 µM
Human transferrin – 10 µg/mL 10 µg/mL
Triiodothyronine – 0.2 nM 0.2 nM
Hydrocortisone – 100 nM 100 nM
Human insulin – 20 nM 20 nM
Dexamethasone – 25 nM –
IBMX – 250 µM –
Rosiglitazone – 2 µM –
5.1.2 3T3-L1 cells
Unlike SGBS cells, 3T3-L1 murine preadipocytes (SP-L1-F ZenBio Inc.)
are a worldwide commonly used cell model for adipobiology study, as they
represent an accurate model of WAT depots with visceral features. Differ-
ent laboratories adopted differentiation medium formulations that varied
in composition and reagent concentration, but the gold standard for 3T3-
L1 is the insulin-dexamethasone-IBMX (isobutylmethylxanthine) cocktail
[129].
The adopted media for culturing 3T3-L1 cells in our laboratory chan-
ged during the 3 years of doctoral studies. This was due to a decline in
differentiation outcome probably linked to cell aging during routinary cell
culture practice [130]. It has to be underlined that all 3T3-L1 cells used
in the studies reported in the present thesis derive from a single stock of
3T3-L1 cells purchased at the beginning of the first year of doctoral study.
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Hence, the variations of the culture media experienced during the research
period come from the time course-dependent need to implement cell differ-
entiation to counteract the unavoidable throwbacks caused by cell senes-
cence. While differentiation media underwent some changes throughout
time, clonal expansion was always performed in high glucose Dulbecco’s
modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin solution (P/S) and 1% amphotericin B. To inhibit fi-
broblast mitosis, 100% confluent cells were switched to the differentiation
cocktail only 48 hours after reaching full confluence.
The first differentiation cocktail adopted in our laboratory has been de-
scribed by Asano and colleagues [131] and has been slightly modified in
reagents’ concentration. The formulation of differentiation and mainte-
nance cocktails are reported in Table 5.2. This formulation has been used
in experiments reported in Chapter 12. The incubation with the differen-
tiation medium lasted three days and the replacement with maintenance
medium was performed until cell sampling.
Table 5.2: Formulation of 3T3-L1 cells culture media modified from Asano et al.
[131]. DMEM/F12: Dulbecco’s modified Eagle medium/Ham’s F12;




Basal medium DMEM/F12 DMEM/F12
FBS 10% 10%
P/S 1% 1%
Amphotericin B 1% 1%
Triiodothyronine 1 nM 1 nM
Human insulin 0.5 µg/mL 0.5 µg/mL
Dexamethasone 5 µM –
IBMX 0.5 mM –
Rosiglitazone 1 µM –
This first differentiation cocktail has been switched to a formulation
closer to the gold standard proposed in late ’70s [132]. This formulation
has been used in experiments described in Chapters 13 and 15 and pro-
duced good differentiation outcomes. Also in this case, the differentiation
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medium was administered for three days and the maintenance lasted un-
til cell sampling. Used reagents and their concentrations are reported in
Table 5.3.
Table 5.3: Formulation of 3T3-L1 cells culture media modified from Rubin et al.
[132]. DMEM/F12: Dulbecco’s modified Eagle medium/Ham’s F12;




Basal medium DMEM/F12 DMEM/F12
FBS 10% 10%
P/S 1% 1%
Amphotericin B 1% 1%
Human insulin 1 µg/mL 1 µg/mL
Dexamethasone 0.5 µM –
IBMX 0.5 mM –
The final differentiation cocktail tested for 3T3-L1 culture is currently
in use in our experiments and is achieving excellent differentiation rates.
The formulation has been derived from Zebisch and colleagues [133] with-
out modifications and it has been used for experiments described in Chap-
ter 14. The incubation with the differentiation cocktail lasted two days,
while maintenance was administered to cell cultures until cell sampling.
The list of reagents and their concentration are indicated in Table 5.4.
Table 5.4: Formulation of 3T3-L1 cells culture media modified from Zebisch et al.
[133]. HG DMEM: high glucose Dulbecco’s modified Eagle medium;




Basal medium HG DMEM HG DMEM
FBS 10% 10%
P/S 1% 1%
Amphotericin B 1% 1%
Human insulin 1 µg/mL 1 µg/mL
Dexamethasone 0.25 µM –
IBMX 0.5 mM –
Rosiglitazone 2 µM –
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5.1.3 X9 cells
Experiments on 3T3-L1 cells and X9 cells (CRL-3282 ATCC) are re-
ported in Chapter 13. These two murine models are different in their
metabolic profile, as X9 cells have been isolated from the subcutaneous
inguinal white fat pad, which is more prone to browning than other de-
pots [80]. Researches using these cell line are lacking in literature, so the
choice of the most appropriate culture medium required a deep study and
comparison between various formulations.
When differentiated with the cocktail recommended by Wu and Xu [134],
the differentiation rate of X9 cells was very low, as about 85% cells pre-
served a fibroblast-like aspect after the incubation with both differentia-
tion and maintenance media. The formulation proposed for the media in
[134] has been reported in Table 5.5.
Table 5.5: Formulation of X9 cells culture media as reported by Wu & Xu [134].
DMEM/F12: Dulbecco’s modified Eagle medium/Ham’s F12; HG
DMEM: high glucose Dulbecco’s modified Eagle medium; FBS: fetal
bovine serum; P/S: penicillin/streptomycin; IBMX:
isobutylmethylxanthine.
Reagent Growth Differentiation Maintenance
medium medium medium
Basal medium DMEM/F12 DMEM/F12 DMEM/F12
FBS 15% 10% 10%
P/S 1% 1% 1%
Amphotericin B 1% 1% 1%
Triiodothyronine – 1 nM 1 nM
Human insulin – 0.5 µg/mL 0.5 µg/mL
Dexamethasone – 5 µM –
IBMX – 0.5 mM –
Rosiglitazone – 1 µM –
For X9 cells, four different media formulations have been tested. They
were taken from [133] and [135] and differed not only in the reagents’ na-
ture and concentration, but also in basal medium composition and FBS
level. Different media will be called to hereafter Formulation (F) 1, F2, F3
and F4 and their reagents’ concentrations are reported in Table 5.6.
To test the effectiveness of each formulation, cells were grown for 2 and
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Table 5.6: Formulation of X9 cells culture media F1, F2, F3 and F4. DMEM/F12:
Dulbecco’s modified Eagle medium/Ham’s F12; FBS: fetal bovine
serum; P/S: penicillin/streptomycin; IBMX: isobutylmethylxanthine.
Reagent F1 F2 F3 F4
Growth Basal medium DMEM/F12 HG DMEM DMEM/F12 HG DMEM
medium FBS 15% 10% 15% 10%
P/S 1% 1% 1% 1%
Amphotericin B 1% 1% 1% 1%
Differentiation Basal medium DMEM/F12 HG DMEM DMEM/F12 HG DMEM
medium FBS 10% 10% 10% 10%
P/S 1% 1% 1% 1%
Amphotericin B 1% 1% 1% 1%
IBMX 0.5 mM 0.5 mM 0.5 mM 0.5 mM
Human insulin 10 ng/mL 10 ng/mL 1 µg/mL 1 µg/mL
Dexamethasone 1 µM 1 µM 0.25 µM 0.25 µM
Triiodothyronine 1 nM 1 nM 1 nM 1 nM
Rosiglitazone 1 µM 1 µM 2 µM 2 µM
Indomethacin 125 µM 125 µM – –
Maintenance Basal medium DMEM/F12 HG DMEM DMEM/F12 HG DMEM
medium FBS 10% 10% 10% 10%
P/S 1% 1% 1% 1%
Amphotericin B 1% 1% 1% 1%
Human insulin 10 ng/mL 10 ng/mL 1 µg/mL 1 µg/mL
Triiodothyronine 1 nM 1 nM 1 nM 1 nM
Reference modified from [135] [135] [133] [133]
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6 days post-differentiation induction and lipid accumulation was evaluated
through oil red O (ORO) staining quantification, according to Mehlem’s pro-
tocol [136]. ORO staining is a protocol that allows the quantification of the
TAG accumulation in cultured cells through a colorimetric measurement of
absorbance.
ORO was filtered with 0.2 µm filters and mixed with H2O in a 6:4 ratio.
The mixture was incubated at room temperature (RT) for 20 minutes and
then filtered again with 0.2 µm filters. In the meantime, cells plated in
96-well plates were fixed with formalin 10% for 5 minutes at RT. Formalin
was then refreshed for a second incubation lasting 90 minutes at RT. Next,
cells were rinsed with 60% isopropanol and wells were let to completely air
dry. ORO:H2O working solution was then added to well and incubated for
10 minutes at RT. After ORO removal, cells were immediately washed 5
times with H2O; following the last cleansing, wells were let to completely
air dry. ORO accumulated in adipocytes was eluted with a 15 minutes
incubation with 100% isopropanol at RT, followed by absorbance detection
with a Spark multimode microplate reader (Tecan Trading AG). Prior to
ORO elution, cells were imaged with a DM4 B optical microscope (Leica
Microsystems GmbH).
ORO internalization by differentiating X9 cells is shown in Figure 5.1.
At 2d, most of X9 cells preserved a fibroblast morphology, but a certain level
of ORO internalization was displayed. At this time point, the formulation
which guaranteed the best lipid accumulation is F4 (Figure 5.1, a). The
presence of a high glucose level in the basal medium has probably been
useful for cell expansion and differentiation, as glucose was internalized
and accumulated in form of triglycerides. At 6d, cells were more differen-
tiated with all media formulations and a higher quantity of ORO was in-
ternalized in LDs (Figure 5.1). Nevertheless, F4 medium, which achieved
the best lipid accumulation at 2d, resulted the least efficient medium at 6d
(Figure 5.1, b), while the most effective media were found to be F1 and F3.
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Figure 5.1: ORO uptake by X9 cells at 2 (2d) and 6 (6d) days of differentiation
with differently formulated differentiation media and its
quantification at 2d (a) and 6d (b). Absorbance data are expressed
as means ± SEM from one-way ANOVA. Capital letters indicate p <
0.0001, small letters indicate p < 0.05.
5.1.4 IMBAT cells
A preliminary methodological study has been performed also on IM-
BAT cells, which are immortalized brown adipocytes isolated from the in-
trascapular fat pad of mice kindly gifted by prof. Mark Christian (Notting-
ham Trent University).
The culture of IMBAT cells presents some substantial differences with
other models, as the initial clonal expansion phase should occur at 33°C.
After the incubation in the differentiation cocktail recommended by prof.
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Christian, cell culture is continued at 37°C. The culture media have been
tested in our laboratory and they gave satisfactory growth and differentia-
tion performances; their formulation is reported in Table 5.7.
Table 5.7: Formulation of IMBAT cells culture media as reported by prof.
Christian. DMEM/F12: Dulbecco’s modified Eagle medium/Ham’s
F12; FBS: fetal bovine serum; P/S: penicillin/streptomycin; IBMX:
isobutylmethylxanthine.
Reagent Growth Differentiation Maintenance
medium medium medium
Basal medium DMEM/F12 DMEM/F12 DMEM/F12
FBS 10% 10% 10%
P/S 1% 1% 1%
Amphotericin B 1% 1% 1%
Triiodothyronine – 1 nM 1 nM
Human insulin – 1 µg/mL 1 µg/mL
Dexamethasone – 250 nM –
IBMX – 0.5 mM –
Rosiglitazone – 2.5 µM –
Indomethacin – 125 µM –
The use of this model will have interesting applications for the current
studies, as they both serve as a reliable positive control in comparison to
treated white and brite cells and can further strengthen data about the




6.1 Lipid droplets analysis
6.1.1 BODIPY staining
4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene (BOD-
IPY) 493/503 is a fluorescent dye that stains neutral lipids in biological
samples. This has been chosen to perform ultrastructural studies on adip-
ocytes imaged at epifluorescence Axio Observer Z1 microscope (Carl Zeiss
GmbH) or SP8 confocal microscope (Leica Microsystems GmbH) equipped
with LAS X software, version 3.1.5.16308.
To perform BODIPY staining, cells grown on microscopy slides were
fixed with a 2% formalin solution diluted in PBS 1X at RT for 15 minutes.
Fixed cells were then rinsed in PBS 1X and incubated with 1 µg/µL BOD-
IPY for 45 minutes at RT in dark. Stained cells were rinsed three times
with PBS 1X and mounted with a Fluoroshield mounting medium with
4’,6-diamidino-2-phenylindole (DAPI).
6.1.2 LD dynamic analysis
A comprehensive and descriptive system to obtain reliable morphologi-
cal data about browning of white adipocytes is the analysis of LD dynamic
in cells. For this purpose, the colorimetric ORO assay cannot provide useful
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data, because it is used mainly to understand the differentiation level of ad-
ipocytes, as it gives a global quantitation of the concentration of TAGs with-
out distinguishing the contribution of each LD. For this reason, the mor-
phology of LDs in this thesis was measured with the MRI_Lipid Droplets
macro for ImageJ software (http://rsb.info.nih.org/ij/) [137], following the
acquisition of images of BODIPY-stained adipocytes. The macro applied a
bandpass filter to the input image by using a Gaussian filter and then scal-
ing the image down and up again with increasing scale. This procedure al-
lowed to apply an automatic threshold to the image, which produced a mask
that removed artefacts. Objects that appeared smaller than a given size
chosen by the user were considered artefacts and consequently removed
from the count. Contacting lipid droplets are separated by a binary water-
shed transformation. Finally, individual LDs in every field are enclosed in
single regions of interest (ROI) for which the software measures the area
surface (Figure 6.1).
Figure 6.1: MRI_Lipid Droplets macro for ImageJ measures simultaneously all
LDs present in the input micrography by enclosing them in discrete
ROIs.
As a raw output, the macro provided a number of data, including the
number of LDs in the input image, their area surface, maximum Feret di-
ameter (MFD) and integrate optical density (IOD). MFD estimated the di-
ameter of irregularly shaped objects [138], while IOD indicated the triglyc-
eride content, as a linear correlation between IOD and lipid content of LDs
has been described [139]. Total area surface occupied by LDs in each input
image has been calculated as the sum of single LD area surfaces. The cell
count allowed the calculation of area surface and number of LDs per cell.
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The average area surface of a single LD was calculated by dividing the area
surface of LDs/cells by the number of LDs/cell.
Morphological data were produced for at least 15 images per experimen-
tal condition and were analyzed as non-parametric data, since they did not
follow the normal Gaussian distribution. Thus, statistical analyses of LD
data were performed with Kruskal-Wallis or Mann-Whitney tests with post
hoc Bonferroni correction of significance, run on SPSS or XLSTAT statisti-
cal softwares. A non-parametric representation of the LD size probability
density function (kernel) was also applied to avoid making assumptions
about the distribution of the data; the kernel size distribution was pro-
duced by a routine written in Matlab 7.1.
6.2 Mitochondrial morphology analysis
6.2.1 MitoTracker staining
MitoTracker® Orange CMTMRos is a selective mitochondrial fluores-
cent dye whose accumulation depends upon membrane potential. The work-
ing solution of choice was prepared by diluting MitoTracker stock solution
in cell growth medium to a final concentration of 100 nM. The incubation
with the dye was performed on live cells prior fixation with formalin. Cells
treated with MitoTracker working solution were incubated in the CO2 in-
cubator for 30 minutes. After the incubation, fixation with 2% of forma-
lin, washing with PBS 1X and mounting with DAPI-Fluoroshield were per-
formed prior imaging at the epifluorescence Axio Observer Z1 microscope.
6.2.2 Analysis of mitochondrial dynamic
The analysis of mitochondrial morphology has been performed with the
ImageJ macro Mito-Morphology [140] for experiments in Chapter 11. 10
images per time point underwent mitochondrial morphology analysis: the
intensity of mitochondria-specific fluorescence produced by MitoTracker
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Orange staining was adjusted with contrast-limited adaptive histogram
equalization (CLAHE) to optimally resolve the pixel constituting each mi-
tochondrion. Measurements produced data about mitochondrial content (%
of cytosol occupied by mitochondria), the area/perimeter ratio (a parameter
that described the level of interconnectivity between mitochondria) and the
area/perimeter ratio normalized to the minor axis, which in turn described
the degree of swelling.
Later investigations unveiled some limitations of this tool. A more
comprehensive analysis was provided by the stand-alone software MicroP,
whose functionality has been described by Peng and colleagues [141]. Im-
ages of MitoTracker-stained cells used as input were semi-automatically
segmented to distinguish mitochondria from nuclei. Each mitochondria-
background image was subsequently segmented to extract mitochondria
with local normalization and Otsu’s thresholding. After this final seg-
mentation step, mitochondria appeared as binary objects which can be
extracted by standard object labeling. Postprocessing of these images re-
moved objects with low intensity and small area surface, which are likely
artefacts.
For each segmented mitochondrion, structural data were produced, in-
cluding area surface, solidity and ratio of skeleton. Solidity has been de-
scribed as the ratio of the mitochondrial area and the area of the virtual box
enclosing the mitochondria: the more this value is close to 1, the more com-
pact is the mitochondrion. Values close to 0 indicate a twisted structure.
The ratio of skeleton indicated the ratio between mitochondrial major and
minor axes and it can be interpreted as an elongation index. The whole set
of quantitative data per each mitochondrion allowed their clustering and
classification into six discrete morphological subtypes (Figure 6.2):
1. small globules: round-shaped mitochondria, that are likely a product
of mitochondrial fission;
2. large globules: swollen globules with a larger area;
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3. simple tubules: straight, elongated mitochondria with no branches;
4. twisted tubules: elongated tubules with a non-linear development in
the cytoplasm;
5. donuts: elongated tubules whose ends fused with each other;
6. branched tubules: complex interconnected mitochondrial structure
with a web-like organization.
Figure 6.2: From an image of MitoTracker Orange-stained cells (left), MicroP
software perform a segmentation with Otsu’s thresholding (middle)
and classifies detected mitochondria into morphological subtypes
(right) as follows: blue: small globules; yellow: large globules; green:
straight tubules; orange: twisted tubules; red: donuts; purple:
branched tubules. Scale bar: 10 µm.
This set of morphological data was more descriptive and has been adopted
in our experiments to quantify the impact of browning treatments on cell
cultures, as presented in Chapter 14. The quantitative data were elab-
orated to evaluate the frequency of each mitochondrial subtype in differ-
entially treated cells, their cumulative area surface and their cumulative
skeletal ratio to effectively present how mitochondrial dynamic was af-




Different treatments administered to cultured cells might affect their
viability. To pinpoint the best concentration of bioactive compounds to be
administerd to cells, the MTT colorimetric viability assay has been chosen.
After removal of culture medium from treated cells, an incubation with
5 mg/mL MTT solution in Hank’s balanced salt solution (HBSS) was per-
formed after a wash in PBS 1X. The incubation was carried out at 37°C
for 4 h. During this period, living cells convert water-soluble, yellow MTT
into a water-insoluble, purple metabolite named formazan; this conversion
is catalyzed by mitochondrial reductases [142]. Accumulated formazan is
dissolved in dimethyl sulfoxide (DMSO) and incubated overnight at 37°C.
The optical density at 550 nm is measured to calculate cell viability, which
is directly proportional to the quantity of formazan produced during incu-
bation with MTT. Statistical differences between differentially treated cells





All gene expression experiments were performed on purified RNA iso-
lated from cell culture. RNA isolation was achieved by cell lysis with 1
mL/10 cm2 TRIzol reagent, which induced a severe breakdown of cellular
structures and preserved the integrity of nucleic acids for a long time, if
stored at –80°C. Cell lysates were then processed with the PureLink™ RNA
Mini Kit following the producer’s protocol to purify the isolated RNA. The
concentration and quality of isolated RNA were measured with a NanoDrop
1000 spectrophotometer (Thermo Fisher Scientific) or with the Spark mul-
tiplate reader.
Gene expression was analyzed either by RT-PCR amplification, followed
by agarose gel band quantification, or by retrotranscription of RNA into
cDNA which was subsequently amplified with real time PCR. The required
primers for PCR amplification were designed on Primer3 Input web tool
[143].
8.1 RT-PCR
RT-PCR was the technique of choice in gene expression analysis of the
experiment presented in Chapter 11, involving the use of human SGBS adi-
pocytes. β-actin was the housekeeping gene of choice and preliminary trials
displayed that its expression was more stable than other housekeeping ge-
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nes in human adipocytes. Moreover, the quantification of its amplicon band
in the agarose gel was more robust and accurate among replicates than flu-
orescence quantitation in real time PCR. RT-PCR was performed using the
SuperScript™ III one-step RT-PCR system. A list of primers designed on
human gene sequences is reported in Table 8.1.
Total RNA is reverse-transcribed and amplified in a PTC-100 thermal
cylcer (MJ Research) with the following reaction conditions:
• cDNA synthesis: 50°C, 30 minutes;
• reverse transcriptase inhibition: 94°C, 2 minutes;
• cDNA amplification: 40 cycles of:
1. cDNA denaturation, 94°C, 30 seconds;
2. primers annealing at different temperatures according to Table
8.1, 30 seconds;
3. primers elongation, 72°C, 30 seconds;
• termination: 72°C, 5 minutes.
Amplified cDNA was then quantified by 1% agarose gel electrophoresis
with GelRed and normalized against β-actin expression. Agarose bands
were measured with the Gel analysis method in ImageJ, which returned
absolute density values. Relative density was subsequently calculated by
dividing the absolute value of the gene of interest for the density of the
housekeeping.
The gene expression analysis was performed on three biological repli-
cates and at least three technical replicates. These expression data ac-
cepted the null hypothesis of Kolmogorov-Smirnov statistical test of nor-
mality, so they were treated as normal parametric values. For this reason,
the statistical significance of differences between genes in each experimen-






























Table 8.1: List of primers used in RT-PCR for human gene amplification. ACTB: β-actin; PPARG1: peroxisome proliferator-activated
receptor γ, variant 1; PPARG2: peroxisome proliferator-activated receptor γ, variant 2; PPARA: peroxisome
proliferator-activated receptor α; PRDM16: PR domain containing 16; PPARGC1A: PPARγ coactivator 1α; UCP1:
uncoupling protein 1; LEP: leptin; ADIPOQ: adiponectin; LIPE: lipase E.
Gene GenBank accession Sequence Amplicon length (bp) Tm (°C)
ACTB JN038572.1 Forward: 5’-CTCTTCCAGCCTTCCTTCCT-3’
Reverse: 5’-AGCACTGTGTTGGCGTACAG-3’
116 59.4
PPARG1 NM_138712.3 Forward: 5’-GCCGCCAGATTTGAAAGAAGC-3’
Reverse: 5’-TGGCATCTCTGTGTCAACCA-3’
110 57.3
PPARG2 NM_015869.4 Forward: 5’-TACAGCAAACCCCTATTCCA-3’
Reverse: 5’-GAGAAGTCAACAGTAGTGAAG-3’
240 55.6
PPARA NM_005036.4 Forward: 5-TCTGTCGGGATGTCACACAA-3’
Reverse: 5’-CGGGCTTTGACCTTGTTCAT-3’
191 57.3
PRDM16 AF294478.1 Forward: 5’-GAGGAGGACGATGAGGACAG-3’
Reverse: 5’-GCTCCTCATCCTCCTCATCC-3’
103 61.4
PPARGC1A NM_001330751 Forward: 5’-GCCCAGGTACAGTGAGTCTT-3’
Reverse: 5’-GTGAGGACTGAGGACTTGCT-3’
105 59.4
UCP1 NM_021833.4 Forward: 5’-GCGGATGAAACTCTACAGCG-3’
Reverse: 5’-GTTTCTTTCCCTGCGGTGAG-3’
117 59.4
LEP D63519.2 Forward: 5’-ACCAAGGTCTTCAGCCATCA-3’
Reverse: 5’-CCCTCTGCCCTCTCTGAAAT-3’
108 58.4
ADIPOQ EU420013.1 Forward: 5’-CCTAAGGGAGACATCGGTGA-3’
Reverse: 5’-GTAAAGCGAATGGGCATGTT-3’
173 57.4
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8.2 Real time PCR
Real time PCR was chosen for murine samples following multiple house-
keeping genes analysis. TATA box-binding protein (Tbp), glyceraldehyde
3-phosphate dehydrogenase (Gapdh) and RPLP0 ribosomal protein (36b4)
were found to be excellent housekeeping genes for murine 3T3-L1 and X9
adipocytes. Their amplification with real time PCR was more effective and
raw expression data were constant and stable among replicates and be-
tween different days of differentiation.
To perform real time PCR, purified RNA was retrotranscribed with ei-
ther ImProm-II™ Reverse Transcription System or Transcriptor High Fi-
delity cDNA Synthesis Kit. Aliquots of the synthesized cDNA have been
pooled and diluted in serial dilutions to perform standard curves in order
to optimize PCR conditions, such as the concentration of both cDNA and
primers. A comprehensive list of primers used in all experiments involv-
ing murine genes is reported in Tables 8.2 and 8.3. Real time PCR was
performed with the Platinum™ SYBR™ Green qPCR SuperMix-UDG in a
96-well spectrofluorimetric CFX thermal cycler (Bio-Rad Laboratories, Inc.)
with the following reaction conditions:
• Platinum™ Taq polymerase activation: 50°C, 2 minutes;
• first cDNA denaturation: 95°C, 10 minutes;
• cDNA amplification: 45 cycles of:
1. cDNA denaturation, 95°C, 10 seconds;
2. primers annealing at different temperatures according to Tables
8.2 and 8.3, 30 seconds;
3. primers elongation, 72°C, 30 seconds;
• termination: 72°C, 5 minutes;
• melting curve construction: 0.5°C increments from 65 to 95°C, 5 sec-





























Table 8.2: List of primers used in real time PCR. Housekeeping genes: Tbp: TATA box-binding protein; Gapdh: glyceraldehyde
3-phosphate dehydrogenase; 36b4: RPLP0 ribosomal protein. Brown & brite fat markers: Ucp1: uncoupling protein 1;
Tbx1: T-box1; Prdm16: proline rich domain containing 16; Elovl3: elongase of very long chain fatty acids 3; Ppara:
peroxisome proliferator-activated receptor α; Ppargc1a: PPARγ coactivator 1α. Mitochondrial genes: Mfn2: mitofusin 2;
Drp1: dynamin-related protein 1; Cyc1: cytochrome C1.
Gene GenBank accession Sequence Amplicon length (bp) Tm (°C)
Tbp NM_013684.3 Forward: 5’-CCAATGACTCCTATGACCCCTA-3’
Reverse: 5’-CAGCCAAGATTCACGGTAGAT-3’
104 58.5
Gapdh NM_008084 Forward: 5’-AATGTGTCCGTCGTGGATCTGA-3’
Reverse: 5’-AGTGTAGCCCAAGATGCCCTTC-3’
117 60.0
36b4 BC099384.1 Forward: 5’-GAAACTGCTGCCTCACATCC-3’
Reverse: 5’-AGGTCTTCTCGGGTCCTAGA-3’
179 59.0
Ucp1 NM_009463.3 Forward: 5’-CTTTGCCTCACTCAGGATTGG-3’
Reverse: 5’-ACTGCCACACCTCCAGTCATT-3’
123 59.8
Tbx1 NM_011532.2 Forward: 5’-AGGCGGAAGGAAGTGGTATT-3’
Reverse: 5’-TACCAGTATCTACACCGCCC-3’
118 58.4
Prdm16 NM_027504.3 Forward: 5’-CCACCAGCGAGGACTTCAC-3’
Reverse: 5’-GGAGGACTCTCGTAGCTCGAA-3’
107 61.4
Elovl3 NM_007703.2 Forward: 5’-TTCTCACGCGGGTTAAAAATGG-3’
Reverse: 5’-GGCCAACAACGATGAGCAAC-3’
139 58.9
Ppara NM_011144.6 Forward: 5’-TCTGTCGGGATGTCACACAA-3’
Reverse: 5’-CGGGCTTTGACCTTGTTCAT-3’
191 57.3
Ppargc1a NM_008904.2 Forward: 5-TATGGAGTGACATAGAGTGTGCT-3’
Reverse: 5’-CTGGGCAAAGAGGCTGGTC-3’
191 60.0
Mfn2 AY123975.1 Forward: 5’-TGTAGCAGGAGGAATGGTGG-3’
Reverse: 5’-TTGTAGCAAGGCAGGGATGA-3’
139 58.4
Drp1 AB079133.1 Forward: 5’-TATGCCAGCAAGTCCACAGA-3’
Reverse: 5’-CACAATCTCGCTGTTCTCGG-3’
98 58.4















Table 8.3: List of primers used in real time PCR (continues). Lipid droplets-associated genes: Cidea: cell death-inducing
DFFA-like effector A; Cidec: cell death-inducing DFFA-like effector C; Plin1: perilipin 1. Receptors: Adrb3: β3
adrenoreceptor; Trpv1: transient receptor potential vanilloid 1; Rara: retinoic acid receptor α; Rarb: retinoic acid receptor
β; Rxra: retinoid X receptor α; Rxrb: retinoid X receptor β. Other genes: Adipoq: adiponectin; Bdnf : brain-derived
neurotrophic factor; Lipe: lipase E.
Gene GenBank accession Sequence Amplicon length (bp) Tm (°C)
Cidea NM_007702.2 Forward: 5’-ATCACAACTGGCCTGGTTACG-3’
Reverse: 5’-TACTACCCGGTGTCCATTTCT-3’
136 58.9
Cidec NM_178373.4 Forward: 5’-ACCTTCGACCTGTACAAGCT-3’
Reverse: 5’-GTGCAGGTCATAGGAAAGCG-3’
99 58.4
Plin1 NM_175640.2 Forward: 5’-TGGACCACCTGGAGGAAAAG-3’
Reverse: 5’-CTTCGAAGGCGGGTAGAGATG-3’
94 60.6
Adrb3 NM_013462.3 Forward: 5’-CCAATGACTCCTATGACC-3’
Reverse: 5’-TTCTGGAGCGTTGGAGAGTT-3’
89 57.3
Trpv1 AY445519.1 Forward: 5’-CGAGATAGGCATAGCACCCA-3’
Reverse: 5’-TGCTTCATGGTGTCCCTCAT-3’
130 58.4
Rara BC010216.1 Forward: 5’-CCGACTTGGTCTTTGCCTTC-3’
Reverse: 5’-TCTCAGCATCGTCCATCTCC-3’
60 59.4
Rarb BC076597.1 Forward: 5’-TTCCTGGATCAATGCCACCT-3’
Reverse: 5’-TTGGGGTCAAGGGTTCATGT-3’
72 57.3
Rxra M84817.1 Forward: 5-TCAGGCAAACACTATGGGGT-3’
Reverse: 5’-GCAGGTGTAGGTCAGGTCTT-3’
87 58.4
Rxrb M84818.1 Forward: 5’-AGACAGCTCCTCCCCAAATC-3’
Reverse: 5’-GTGCTGAAGGGGTAAGAGGT-3’
80 59.4
Adipoq BC028770.1 Forward: 5’-AGGGAGAGAAAGGAGATGCAG-3’
Reverse: 5’-AGTCCCGGAATGTTGCAGTA-3’
81 60.0
Bdnf NM_007540.4 Forward: 5’-ATTACCTGGATGCCGCAAAC-3’
Reverse: 5’-CCTTCCTTGGTGTAACCCAT-3’
241 58.5
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Gene expression was calculated with the ΔΔCt method [144]: the cy-
cle threshold (Ct) of amplified genes was normalized against the geometric
mean of Ct of selected housekeeping genes (ΔCt) and then the ΔCt of con-
trol samples was subtracted to theΔCt of treated samples (ΔΔCt). Relative
fold change of analyzed genes was obtained by calculating 2–ΔΔCt.
Expression data were generated from biological triplicates and repre-
sented similar results from at least three independent experiments. As for
gel band quantitation, the relative fold change data were analyzed as para-
metric data with one- or two-ways ANOVA, followed by post hoc Bonferroni
correction or Tukey’s range test.
In Chapter 13, gene expression data underwent enrichment analysis
through FunRich 3.1.3 tool [145]. This software clustered the input ex-
pression data into biological processes (BPs), calculating the percentage of
annotated protein and the p-value in each BP after Bonferroni correction.
The raw list of BPs was screened and most significant ones, with a rele-
vance for the browning study, were extracted and further analyzed with a
principal component analysis (PCA). The output of PCA was a distance bi-
plot that clustered significant BPs with relative fold change data per each




The detection of expressed proteins in cellular specimens was mainly
performed through immunofluorescence, which allowed to observe posi-
tive immunoreaction and the cellular localization of proteins. During the
last year of Ph.D, it has been studied and delineated a protocol for in-cell
Western (ICW), a protein detection technique that merged the immunoflu-
orescence protocol with the protein quantification that is made possible by
Western blot analysis.
9.1 Immunofluorescence
Cells grown on slides were rinsed in PBS 1X and fixed with 2% formalin.
After fixation, cells were washed twice with PBS 1X supplemented with
0.05% TWEEN 20 (PBST) and permeabilized for 10 minutes at RT with
0.1% Triton X-100. Autofluorescence induced by the aldehyde-based fixa-
tive has been quenched with 0.3 M glycine or 50 mM ammonium chloride
for 15 minutes at RT. Then, an incubation for 1 hour at RT with a blocking
solution containing 10% FBS and 5% normal goat (NG) serum was per-
formed to avoid the background labeling of secondary antibody. The slides
were then incubated with the primary antibody diluted in blocking solu-
tion overnight at 4°C in a moist chamber. A list of used primary antibodies
has been reported in Table 9.1. The following day, cells were washed in
63
CHAPTER 9. PROTEIN EXPRESSION
PBST 1X and incubated for 45 minutes at RT in dark with a fluorescently-
labeled secondary antibody. These antibodies included anti-rabbit Alex-
aFluor® 555 and anti-rabbit fluorescein made in goat for the reaction with
primary antibodies, and anti-mouse fluorescein IgM against secondary an-
tibodies. Labeled cells were then washed in PBST 1X and mounted with
DAPI-Fluoroshield. The subsequent imaging was performed with the epi-
fluorescence Axio Observer Z1 microscope.
9.2 In-cell Western analysis
Quantification of proteins through ICW was performed on cells plated
on a 96-well plate. After culture medium removal, cells were rinsed once in
PBS 1X and fixed with 2% formalin for 15 minutes at RT. Cells were then
washed in PBST 1X for 5 minutes while shaking and subsequently per-
meabilized with 0.1% Triton X-100 for 5 minutes. Following four washes
in PBST 1X, cells were incubated with a blocking solution containing 1%
(bovine serum albumin) BSA and 5% NG. The incubation with primary an-
tibodies (reported in Table 9.1) lasted 2 hours at RT while shaking. A back-
ground control was established by incubating selected wells with blocking
solution. After four washes in PBST 1X, cells were incubated with the sec-
ondary antibody for 1 hour at RT in dark. The secondary antibody was an
anti-rabbit IRDye® 800CW labeled IgG made in goat and specific for near
infrared detection of protein positivity during ICW imaging.
The detection of fluorescence was performed on an Odyssey® CLx imag-
ing system (LI-COR Inc.) for Western blot equipped with Image Studio™
software. Data have been acquired and analyzed by running an automatic
routine specific for ICW.
The relative protein % produced by Image Studio™ was normalized
against the expression of a housekeeping protein (α-tubulin) and data were





















Table 9.1: List of primary antibodies used in immunofluorescence and ICW experiments. PPARγ: peroxisome proliferator-activated
receptor γ; PLIN1: perilipin 1; UCP1: uncoupling protein 1; TRPV1: transient receptor potential vanilloid 1; PGC-1α:
PPARγ coactivator 1 α.
Antibody Type Synthesis Code Purchased from
Anti-PPARγ Rabbit polyclonal Raised against C-terminal amino acids 311-500 of bovine
PPARγ.
PAA886Bo01 Cloud-Clone Corp.
Anti-PLIN1 Rabbit polyclonal Raised against N-terminal amino acids 1-300 of human
PLIN1.
sc-67164 Santa Cruz Biotechnology
Anti-UCP1 Rabbit polyclonal Raised against amino acids 145-159 of human UCP1. ab10983 Abcam
Anti-TRPV1 Mouse monoclonal Generated against N-terminal amino acids 1-130 of rat
TRPV1.
sc-398417 Santa Cruz Biotechnology
Anti-UCP1 Rabbit polyclonal Raised against amino acid sequence from 1 to 299 of human
UCP1
PA5-29575 Thermo Fisher Scientific
Anti-PGC-1α Rabbit polyclonal Raised against a 17 amino acid sequence close to the N-
terminus of human PGC-1α
GTX31921 GeneTex
Anti-α tubulin Rabbit polyclonal Generated from an amino acid sequence within residues 400





The measurement of intracellular Ca2+ in cells has been performed when
analyzing samples treated with capsaicin, because its membrane receptor
TRPV1, when activated, triggers a Ca2+ influx (see Chapter 13). To mea-
sure intracellular Ca2+, the calcium probe Fluo-8 AM has been chosen. Live
cells were incubated with the probe that, once uptaken by cells, was cleaved
of its amphipathic region and became active, emitting fluorescence when
associated to a Ca2+ ion [146]. It was excited at 490 nm and emitted at 520
nm.
After culture medium removal, the staining with a 4 µM Fluo-8 AM
working solution in HBSS supplemented with 15 mM HEPES was per-
formed for 1 h at 37°C. Stained cells were then rinsed with HEPES-HBSS
and immediately imaged.
The acquisition of Fluo-8-treated cells was performed as a time lapse
imaging at the epifluorescence Axio Observer Z1 microscope, which pro-
duced a movie that lasted 180 seconds. This experiment required a first
acquisition of untreated Fluo-8-stained cells to acquire the baseline fluo-
rescence, followed by the administration of the treatment during the acqui-
sition itself (12-14 seconds after the beginning of the acquisition) to appre-
ciate real time changes in cellular fluorescence induced by Ca2+ movements
across plasma membrane.
The analysis of fluorescence signals was performed with ImageJ soft-
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ware, which separated the single frames of the movie creating a stack. To
visualize the fluorescence signal, the brightness and contrast of the stack
were automatically corrected. By creating a Z-projection of the standard de-
viation of all the frames composing the stack, the user appreciated which
cells displayed a variation in fluorescence intensity. Those cells showing
a significant signal were manually added to the ROI manager tool for the
measurement. The standard deviation was the parameter of choice because
it displayed the intensity of the variation of fluorescence only in cells that
actually showed such variation. Cells that did not respond to either the
treatment or the staining with Fluo-8 did not display a difference in fluo-
rescence intensity, so their standard deviation equaled to 0.
The ratio between the maximum fluorescence intensity emitted after
the addition of the compound (F) and the average of baseline fluorescence
(F0) was plotted to visually describe the cell-specific variations in fluores-






SGBS cells as a browning model
The Simpson-Golabi-Behmel syndrome (SGBS) cell strain is an in vitro
model of human white preadipocytes. This strain has been established in
2001 by Wabitsch and colleagues, who isolated preadipocytes from the sub-
cutaneous adipose tissue of a SGBS-affected pediatric patient [127].
SGBS is caused by deletions or point mutations of the X-linked glypican
3 gene (GPC3), located in Xq26. The causative mutations may also involve
the gene glypican 4 (GPC4), which is 120 kb downstream from GPC3 [148].
The different levels of mutation that can affected these genes produce a
variable range of symptoms: while the mild form is associated with long-
term survival, more aggressive forms of this syndrome cause early death
[149]. These forms are characterized by pre- and post-natal macrosomia,
coarse facial features and different levels of skeletal, visceral and neurolog-
ical abnormalities. A number of cases of SGBS-associated gastrointestinal
anomalies, renal malformations, hepatocellular carcinoma, Wilms tumor
and mental retardation have been reported [149–151].
The singular behavior of SGBS cells relies on the GPC3 mutation: it has
been reported that cells mutated for this gene show enhanced hedgehog
signaling pathway [152], a positive regulator of body growth, and dipep-
tidyl peptidasic activity of CD26, which is positively correlated to cell pro-
liferation [153]. In fact, despite these cells are neither immortalized nor
transformed, they retain the ability to expand and differentiate into ma-
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ture adipocytes for a high number of generations. For this reason, SGBS
cells are an excellent model for the study of obesity and cancer and have
been extensively used in recent years [154].
More recently, another unique feature of SGBS cells has been described.
During differentiation, these adipocytes exploit a transient brown-like phe-
notype without any kind of stimulation [155, 156]. Around the 14th day of
differentiation, the expression of canonical BAT markers, such as UCP1,
sharply increases. The expression levels of these markers decreases around
the 28th day of differentiation, when the original white phenotype is re-
stored [155].
The aim of the present research is to gain further knowledge of the
phenotypic switch that characterizes these cells by analyzing the dynamic
changes in LD and mitochondrial morphology. This aspect, despite not be-
ing investigated in previous studies, is of outstanding importance because
one of the main features of WAT browning is a dynamic reorganization of
LDs and mitochondria. This investigation is corroborated with the expres-
sion analysis of selected browning markers.
SGBS cells were grown as described in Section 5.1.1 and cell sampling
occurred at 0, 7, 14 and 21 days following the induction of differentiation
(D0, D7, D14 and D21). The results of this research have been published
in Histochemistry and Cell Biology in 2018 as an original research article
[99]. Briefly, this study confirmed previous findings about the changeful
phenotype of SGBS cells [155, 156], corroborating them with a structural
analysis of changes in LD and mitochondrial morphology. Both organelles
display structural variations coherently with the onset of a brown fat-like
phenotype [92, 103]. In conclusion, this research work provided a new in-
sight of SGBS cells browning attitude, stressing the need to pay attention
in their use as a model when testing browning factors [99].
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Chapter 12
The browning factor BAIBA
Physical exercise has been shown to have many health benefits, as it
increases metabolic rate, improves glucose homeostasis and increases in-
sulin sensitivity. Recently, endocrine factors called myokines, produced
by skeletal muscles and released during their contraction, have been de-
scribed and actively participate in the loss of fat mass through thermogen-
esis[109, 157].
The β-aminoisobutyric acid (BAIBA) is a non-protein amino acid derived





Recently, it has been demonstrated that BAIBA promotes browning of
white adipocytes, lipid oxidation in hepatocytes and has a protective role
against insulin resistance [122]. Moreover, it preserves osteocytes from re-
active oxygen species (ROS)-induced apoptosis [159]. The role of myokines
in enhancing lipid metabolism and promoting the recruitment of thermo-
genic adipocytes has been deeply studied and reviewed [109, 160]. Nev-
ertheless, the cellular pathways in adipocytes activated by the interaction
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with circulating myokines is still mostly unknown. Roberts and colleagues
proposed a PPARα-dependent pathway through which BAIBA achieves its
positive effects on adipocytes and hepatocytes [122]. Despite this observa-
tion, the exact signaling pathway involving BAIBA needs further investi-
gation, as well as the role that BAIBA has on affecting LD dynamic in ad-
ipocytes. This research aims to elucidate the browning effect of BAIBA on
3T3-L1 preadipocytes during their differentiation into mature fat cells by
analyzing the modifications of cytomorphological parameters of LDs and
the expression of a selected panel of marker genes. The analyzed genes
included brown fat-specific markers (Ucp1, Cidea, Elovl3, Prdm16), the
brite marker Tbx1, genes related to mitochondrial biogenesis and func-
tionality (Ppargc1a, Cyc1), genes expressing LD-associated proteins (Cidec,
Plin1) and brain-derived neurotrophic factor (Bdnf ), a neurotrophin whose
browning activity has been investigated in vivo and displayed a role in
regulating energy balance and insulin signaling [123, 161]. For this ex-
periment, 3T3-L1 cells were cultured with the medium reported in Table
5.2. Concomitantly with the switch from differentiation to maintenance
medium, cells were treated with different concentrations of BAIBA in a
racemic mixture; selected concentrations were 1, 3 and 5 µM, as deduced
from the work by Roberts and colleagues [122]. Treated cells were ana-
lyzed at 4 (4d), 8 (8d) and 10 days (10d) after the induction of differenti-
ation, which correspond respectively to 2, 6 and 8 days of incubation with
the active molecule. A negative vehicle control was established by the sup-
plementation of H2O to the medium.
The results on 3T3-L1 cells treated with BAIBA were published in the
European Journal of Histochemistry in 2018 [162] and showed that dif-
ferent BAIBA doses administered to cultured cells for different times of
exposure produced a variety of outcomes. In terms of LD dynamic and ex-
pression of browning markers, the 5 µM dose was the most effective during
early differentiation of 3T3-L1 cells. The browning effect of the compound
decreased in following days of exposure and disappeared at 10 days after
72
the induction of differentiation. This research highlighted the early effect
of BAIBA in inducing WAT browning and brought new evidence about it
lack of effectiveness after prolonged exposure.
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Chapter 13
Browning effect of capsaicin
Adipose tissue browning research is currently focused in the detection of
endogenous and exogenous substances that can recruit thermogenic adipo-
cytes in both BAT and WAT. Natural compounds are an interesting target
in this research, as they can be included in functional foods with therapeu-
tic properties [109].
Capsaicin is an alkaloid found in the fruit of Capsicum spp. (hot pep-






Its biological effects are due to its interaction with the transient receptor
potential vanilloid 1 (TRPV1). This receptor is mainly found in peripheral
sensory neurons involved in pain sensation [164] and it is also extensively
distributed in the gastrointestinal tract [165] and in AT [166]. After the in-
teraction with its ligands, adipose TRPV1 opens its ion channel, causing an
intracellular influx of Ca2+. The high intracellular Ca2+ concentration acti-
vate the Ca2+/calmodulin-activated protein kinase (CaMKII), which in turn
phosphorylates AMPK and, eventually, sirtuin 1 (SIRT1). Phosphorylated
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SIRT1 promotes the deacetylation of PRDM16 and PPARγ. When active,
these two transcription factors interact with each other and promote Ucp1
expression [125]. Capsaicin triggers an indirect browning stimulation also
when interacting with gastrointestinal TRPV1: the signal produced in the
guts is transmitted through CNS to WAT depots following the activation of
sympathetic adrenergic pathway [126].
The browning potential of capsaicin on white adipocytes has been re-
cently elucidated [125, 167], but long-term effects need further investiga-
tion. Moreover, the effect of capsaicin on LD remodeling and on the expres-
sion of LD-associated proteins have not been properly studied.
This research enriches previous results on the browning effect of cap-
saicin by studying it on two different cell models: 3T3-L1 and X9 murine
cells. These lines differ in their origin and could show different responses
to browning stimulation, being X9 cells responsive to browning stimuli,
as they were isolated from an inguinal depot [80]. Conversely, 3T3-L1 cells
display features of multiple adipocytes lineages following appropriate stim-
ulation [168]. The changes in LD dynamics and gene expression profile
after the administration of different doses of capsaicin have been analyzed
between two times of differentiation. Finally, long-term effects of capsaicin,
in combination with norepinephrine, were also tested.
Cell culture was achieved with conditions reported in Table 5.3 for 3T3-
L1 and in Table 5.5 for X9 cells. Treatment of both cell lines with cap-
saicin (CP) and norepinephrine (NE), alone or in combination, started at
day 3 of differentiation, concurrently with the switch from the differenti-
ation medium to the maintenance one and lasted until analysis either at
4 days of differentiation (4d), 1 day of treatment, or at 8 days of differen-
tiation (8d), 5 days of treatment. Experimental groups were identified by
adding to the maintenance medium different combinations of compounds.
A vehicle negative control (CTRL) was established by adding to the main-
tenance medium absolute ethanol (1:1000 dilution). The positive control
was represented by cells treated with 10 µM norepinephrine (NE). Cap-
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saicin concentrations were tested at 0.1 µM (0.1CP) and 1 µM (1CP). These
doses were found to be effective in triggering a brite phenotype on differ-
entiating 3T3-L1 cells [167], but have never been tested neither on mature
3T3-L1 adipocytes nor on X9 cells. The two compounds were also combined
into two additional treatments (0.1CPNE and 1CPNE) to understand if any
synergies or antagonisms between the two factors could occur and to mimic
the cold-independent adrenergic response that CP is able to trigger in vivo
[124] (Figure 13.1).
Figure 13.1: Cell culture treatment protocol. Cells were grown until 90% (X9) or
100% (3T3-L1) confluence. Differentiation lasted 3 days. From day
3, cells were incubated with maintenance medium supplemented
with different treatments lasting for one (4d) or 5 days (8d).
The results of this research have been published in Frontiers in Phys-
iology, section Lipid and Fatty Acid Research, in 2019 [169]. The study
highlighted important differences in the response of the two cell models to
different treatments. 3T3-L1 cells responded to 1CP treatment ad 8d with
a significant up-regulation of Ucp1 and other browning markers, while the
incubation with NE, alone or in association with capsaicin, did not signif-
icantly affect gene expression. Conversely, capsaicin treatments coupled
with NE significantly reduced LD area surface and size at 4d. Capsaicin
treatments on X9 cells poorly affected their gene expression; browning
markers were significantly over-expressed following NE exposure. Also LD
measurements were significantly affected by NE alone or in combination
with capsaicin doses.
The measurement of intracellular Ca2+ influx in 3T3-L1 cells confirmed
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the activation of TRPV1 receptor following capsaicin exposure, although
this result should be further stressed by treating cells with a TRPV1 in-
hibitor, i.e. capsazepine. Nevertheless, preliminary promising results of
TRPV1 inhibition in 3T3-L1 adipocytes have been already described by Ba-
boota and colleagues [167].
In conclusion, 3T3-L1 cells activated a brite phenotype following direct
capsaicin exposure, while X9 cells were insensitive to this treatment and
responded only to the incubation with NE.
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Chapter 14
The browning action of
myokine BDNF
14.1 Introduction
Brain-derived neurotrophic factor (BDNF) is a member of the neurotro-
phin family of growth factors, which have a role in nerve growth regulation
and synaptic plasticity [170]. BDNF and its receptor tropomyosin-related
kinase B (TrkB) are abundantly expressed in neuronal cells, including neu-
rons in energy homeostasis centers within the hypothalamus [171]. Re-
cently, it has been pointed out that BDNF is not only expressed in the
nervous system, but also in other tissues like skeletal muscles [172] and
adipose tissue [173]. Now it has been established the role of BDNF in me-
diating the whole body adaptive responses to variations in energy intake
and expenditure [174]. For instance, BDNF directly affects cells with a role
in glucose metabolism, such as β cells, hepatocytes and skeletal muscle,
towards a hypoglycaemic phenotype [174].
Concerning adipose metabolism, hypothalamic BDNF up-regulates UCP1
levels in BAT, promoting energy expenditure [175], and can promote WAT
browning through sympathetic neuron activation in response to environ-
mental stimuli [123]. In addition to neuronal-mediated metabolic effects,
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BDNF can regulate peripheral energy metabolism by directly affecting non-
neuronal cells, like adipocytes themselves.
Being synthesized also in skeletal muscles during their contraction,
BDNF has been classified as a myokine that acts as an autocrine factor
to improve mitochondrial fat metabolism [176].
Clearly, BDNF has a key role in regulating metabolism of non-neuronal
tissues, but the mechanisms of action and the involved pathways still de-
serve a deeper understanding.
3T3-L1 cells were cultured with the medium formulation reported in
Table 5.4. At the 6th day of supplementation of the maintenance medium,
3T3-L1 cells were fully differentiated into mature adipocytes. At this point,
cells were treated with 1 ng/mL BDNF for 3 (BDNF_3h) or 24 (BDNF_24h)
hours. The choice of BDNF dose was performed by analyzing freely accessi-
ble data of murine pro-B cells transfected with TkrB. The ED50 calculated
for these non-neuronal cells was 0.2–2 ng/mL. A negative vehicle control
was established by treating cells with PBS 1X and a positive control was
realized by incubating cells with 1 µM NE for 3 hours.
14.2 Results
14.2.1 mRNA and protein expression
Relative fold change of tested genes is reported in Figure 14.1. The
relative fold change of Adipoq was mostly uneffected by different treat-
ments. The browning markers Ucp1 (p < 0.0001 vs CTRL and NE), Tbx1 (p
< 0.0001 vs CTRL, p < 0.01 vs NE) and Prdm16 (p < 0.0001 vs CTRL and
NE) are up-regulated in BDNF_3h cells. Their expression is significantly
increased also in BDNF_24h cells (p < 0.0001 vs NE; p < 0.05 vs CTRL;
p < 0.05 vs CTRL, respectively) (Figure 14.1, a). The lower Ucp1 relative
fold change reported in BDNF_24h cells with respect to BDNF_3h corre-
sponded to a significantly higher protein content (p < 0.01 vs CTRL, p <
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0.0001 vs NE), as detected by ICW (Figure 14.2).
Ppargc1a expression was significantly lower vs NE in BDNF-treated
cells at both time points (p < 0.0001) (Figure 14.1, a). Conversely, the PGC-
1α content was significantly elevated in BDNF_24h samples (p < 0.01 vs
NE) (Figure 14.2).
Mfn2 was significantly down-regulated in BDNF_24h cells (p < 0.0001
vs CTRL and NE), while Drp1 expression did not report any significant
variation (Figure 14.1, a).
The expression of brown marker and LD-associated gene Cidea was sig-
nificantly elevated in BDNF_3h cells (p < 0.01 vs CTRL). Conversely, Cidec
expression did not significantly vary among treatments, despite Plin1 rel-
ative fold change showed the same trend, but significant differences were
displayed by BDNF_3h and BDNF_24h (p < 0.01 vs CTRL) (Figure 14.1,
b). The administration of BDNF up-regulated the adipocyte-specific Bdnf
expression in an autocrine fashion, with significant differences at both 3
hours (p < 0.01 vs CTRL) and 24 hours (p < 0.05 vs NE) (Figure 14.1, b).
14.2.2 Mitochondrial morphology
The output of MicroP software was processed in order to depict morpho-
logical differences among samples that underwent various treatments. Mi-
tochondrial area surface, mitochondrial number, elongation index and so-
lidity were analyzed to classify mitochondrial subtypes detected by the soft-
ware. These include small globules, large globules, simple tubules, twisted
tubules, donuts and branched tubules.
Mitochondrial subtypes
Figure 14.3 presents the % of mitochondrial subtypes in controls and in
BDNF-treated cells.
The relative % of total mitochondria ranged from 18.94% (CTRL) to
29.02% (BDNF_24h). Small globules significantly increased in NE (p <
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Figure 14.1: Differentially expressed genes in BDNF-treated cells and controls
(CTRL and NE). (a) Relative fold change of brown markers and
mitochondrial dynamic-related genes. (b) Relative fold change of
LD-associated genes, Adipoq and Bdnf. Data from one-way ANOVA
with post-hoc Tukey HSD correction are presented as LS means of
relative fold change ± SEM. *** p < 0.0001 vs CTRL; ** p < 0.01 vs
CTRL; * p < 0.05 vs CTRL; §§§ p < 0.0001 vs NE; §§ p < 0.01 vs NE;
§ p < 0.05 vs NE.
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Figure 14.2: Relative percentage of proteins detected by ICW. The percentage of
proteins has been normalized against the expression of α-tubulin as
an internal housekeeping. Data from one-way ANOVA with
post-hoc Tukey HSD correction are presented as LS means of
relative % of protein ± SEM. ** p < 0.01 vs CTRL; §§§ p < 0.0001 vs
NE; §§ p < 0.01 vs NE.
Figure 14.3: Presence of different mitochondrial subtypes in BDNF-treated and
in control cells. Data are presented as the ratio of mitochondrial
subtypes relative to the total number ± SEM. Statistical
significance was determined through two-tailed t-test vs positive
and negative controls. ** p < 0.01 vs CTRL; * p < 0.05 vs CTRL; § p
< 0.05 vs NE.
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0.05 vs CTRL) and in BDNF_24h cells (p < 0.01 vs CTRL and p < 0.05 vs
NE). This result might account for an increased mitochondrial fission in
these samples, since the presence of tubular structures was reduced. This
was particularly true for branched tubules, which were significantly less
present in BDNF_24h cells (p < 0.05 vs NE). Large globules decreased sig-
nificantly in NE (p < 0.05 vs CTRL) and BDNF_24h (p < 0.01 vs CTRL)
treatments, indicating reduced swelling phenomena. A sensitive, although
not always statistically significant, decrease relative to CTRL cells has
been observed for twisted tubules and donuts (p < 0.05 vs NE in BDNF-
treated samples). Taken together, these results outlined a distribution of
mitochondrial subtypes coherent with fission events in 3T3-L1 cells that
were incubated with NE and with BDNF for 24 hours.
Mitochondrial area surface
The analysis of mitochondrial area surface per each subtype can provide
useful information about the dynamic of each morphological type following
the administration of a browning compound.
The distribution of mitochondrial area surface is presented in Figure
14.4. The area surface of small globules in BDNF_24h cells was signifi-
cantly higher than in controls (p < 0.01 vs CTRL and p < 0.05 vs NE); by
contrast, the area surface of branched tubules was the significantly lowest
in the same sample (p < 0.01 vs both CTRL and NE). Simple tubules (p <
0.05 vs both CTRL and NE) and twisted tubules (p < 0.01 vs both CTRL
and NE) had a significantly larger area surface in BDNF_24h, although
the total area surface of twisted tubules was substantially lower compared
to other mitochondrial subtypes. In the same sample, donuts displayed
a significantly low area surface (p < 0.01 vs CTRL and p < 0.05 vs NE).
BDNF_3h sample displayed a similar trend in mitochondrial area surface
distribution, in particular in branched tubules (p < 0.05 vs CTRL), donuts
(p < 0.05 vs both CTRL and NE) and simple tubules (p < 0.05 vs CTRL),
while small globules were not significantly different from control cells. De-
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Figure 14.4: Distribution of total mitochondrial area surface among treatments
and different morphological subtypes. Data are presented as the
ratio of area relative to the total area ± SEM. Statistical
significance was determined through two-tailed t-test vs negative
and positive controls. ** p < 0.01 vs CTRL; * p < 0.05 vs CTRL; §§ p
< 0.01 vs NE; § p < 0.05 vs NE.
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spite this, the area surface of large globules in BDNF_3h was significantly
higher compared to controls (p < 0.05 vs NE).
Figure 14.5 reports the cumulative frequency of morphological subtypes’
area surface among different bins of area, flanked by boxplots showing the
differences of medians, first-to-third quartiles and the most extreme values
within the interquartile range among samples. Small globules in NE and
BDNF_24h samples displayed the lowest area surface compared to other
treatments (p < 0.0001), as their cumulative frequency was higher in low
bins of area surface. A similar pattern occurred also in large globules,
where their area in BDNF_24h was the significantly lowest (p < 0.0001).
The pattern of simple and twisted tubules was quite similar to each other:
the area surface of NE and BDNF_24h cells was significantly lower and
showed little or no statistical difference among them. Nevertheless, the
abundance of mitochondria with small area surface was higher in BDNF_24h
sample.
BDNF_24h had a substantially minor area surface (p < 0.0001) in donuts
compared to other treatments; this was also evident from the cumulative
frequency curve, as this sample reached the highest frequency in small bins
of area surface. A similar trend was observed also in branched tubules (p <
0.0001).
In summary, results about the area surface of mitochondrial subtypes
showed that NE and BDNF_24h cells had the lowest area for most of mor-
phological subtypes, especially in tubular-shaped mitochondria. This fea-
ture confirmed previous assumptions about the onset of mitochondrial fis-
sion.
Elongation index of mitochondria
The elongation index is a parameter that quantifies the degree of elon-
gation of a mitochondrion: higher values account for elongated mitochon-
dria. This index is calculated by MicroP as skeletal ratio, that is the ratio
between the major and the minor axes of the selected mitochondrion. Fig-
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Figure 14.5: Cumulative frequency of total area surface of mitochondrial
subtypes. In boxplots is showed the difference between medians,
first-to-third quartiles and the most extreme values within the
interquartile range among treatments. Statistical significance in
boxplots was determined through Kruskal-Wallis statistical test
with Bonferroni correction. *** p < 0.0001; ** p < 0.01; * p < 0.05.
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ure 14.6 presents the cumulative frequencies of the elongation index among
mitochondrial subtypes and treatments.
Figure 14.6: Cumulative frequency of elongation index of mitochondrial
subtypes. In boxplots is showed the difference between medians,
first-to-third quartiles and the most extreme values within the
interquartile range among treatments. Statistical significance in
boxplots was determined through Kruskal-Wallis statistical test
with Bonferroni correction. *** p < 0.0001; ** p < 0.01; * p < 0.05.
The elongation index of small globules was the lowest in BDNF_3h
sample (p < 0.0001), as the highest frequency of this morphological sub-
type was detected in low clusters of skeletal ratio. The differences of the
elongation index in large globules were not significant; in fact, the cu-
mulative frequency curves were overlapping. Simple tubules and twisted
tubules displayed a trend similar to that observed for small globules: also
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in this case, the lowest elongation index was displayed in BDNF_3h cells
(p < 0.0001). No significant differences were displayed among controls and
BDNF-treated cells in elongation index for donuts, even if the cumulative
frequency curve of BDNF_3h cells was clearly shifted to less elongated mi-
tochondria, indicating that the majority of donuts in this sample displayed
a small elongation index. In branched tubules, the elongation index was
higher in CTRL and BDNF_3h treatments and lower in BDNF_24h (p <
0.0001).
The results about mitochondrial elongation interestingly showed a time
point-dependent reduction of skeletal ratio in BDNF-treated cells, as those
incubated with BDNF for 3 hours displayed the lowest elongation.
Discriminant analysis
Key morphological features of mitochondria might significantly indicate
the way 3T3-L1 cells respond to different treatments. To determine the ex-
tent of treatment-specific variations in an unbiased manner, the percentage
of area surface, elongation index and solidity of each mitochondrial sub-
types were integrated into a single multivariate model through discrimi-
nant analysis (DA) (Figure 14.7).
The model captured 85.53% of the total variance in the dataset and
achieved a clear separation between different samples. Rank ordering of
the variable importance in projection (VIP) scores for each parameter iden-
tified the most important morphological features that discriminate each
sample. These data have been reported in Table 14.1.
The most impacting features were those relative to small globules and,
to a lesser extent, twisted or branched tubules: the parameters with the
lowest Wilk’s lambda display the strongest discriminant power (Table 14.1)
[177, 178].
This analysis suggested that the largest part of the variance among
treatments concerning mitochondrial dynamic relied on the architecture
of small globules and twisted or branched tubules.
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Figure 14.7: Sample clustering produced by discriminant analysis with
multivariate modeling of mitochondrial subtypes and their
morphological features. Centroids are reported as yellow dots.
Table 14.1: Significant VIP in discriminant analysis illustrating the contribution
of different morphological features to the separation of differentially
treated cells. The most discriminant parameters have a low Wilk’s
lambda and a high F.
Morphological variable Mitochondrial subtype Wilk’s lambda F p-value
Area Small globules 0.328 12.280 0.000
Area Large globules 0.494 6.156 0.005
Area Simple tubules 0.564 4.629 0.014
Area Twisted tubules 0.401 8.944 0.001
Area Branched tubules 0.395 9.188 0.001
Elongation Small globules 0.352 11.061 0.000
Elongation Large globules 0.552 4.868 0.012
Elongation Simple tubules 0.596 4.075 0.023
Elongation Twisted tubules 0.521 5.520 0.007
Solidity Small globules 0.382 9.716 0.000
Solidity Large globules 0.578 4.379 0.018
Solidity Donuts 0.508 5.813 0.006
Solidity Branched tubules 0.417 8.395 0.001
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14.3 Discussion
This study provided interesting preliminary results on the browning
effect of ectopic BDNF administration to cultured white adipocytes. In par-
ticular, the analysis of the expression profile of selected target genes is
supported by a thorough evaluation of changes in mitochondrial structure,
which showed morphological characteristics close to the typical brown ones.
The expression of adiponectin has been used as a marker of differentiation:
since its mRNA level has not been affected by the treatments, we can infer
that cells were completely differentiated.
Results produced by gene and protein expression analyses showed in-
teresting patterns in BDNF-treated 3T3-L1 cells. The rise of the mRNA of
canonical brown markers is significantly higher after 3 hours of incubation
with BDNF. Conversely, the UCP1 protein content after 3 hours of incuba-
tion is the lowest, while it increases after 24 hours of incubation. Possi-
bly, the protein traslation happens later than mRNA transcription [179].
This also occurred with PGC-1α: the lowest mRNA expression after the
24 hours treatment is flanked by the significantly highest protein level at
the same time point [180]. Hence, the high protein content of PGC-1α in
BDNF-treated 3T3-L1 cells could account for an increased mitochondrial
biogenesis, which is a typical feature of brite adipocytes recruitment [181].
This result is in agreement with the increased rate of mitochondrial con-
tent (29.02% in BDNF_24h and 18.94% in CTRL).
The alterations in the expression of mitochondria-related genes depict
a more fissed phenotype in BDNF-treated cells. Mfn2 expression is the sig-
nificantly lowest among treatments. Since this gene encodes for a protein
that participates in mitochondrial fusion [101], its down-regulation may be
directly linked to a decrease in fusion events. This phenotype has been
observed in thermogenic adipocytes [103], but in the present research, the
expression of Drp1, the regulator of mitochondrial fission, has not been sig-
nificantly impacted by the administration of BDNF. This is not coherent
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with the results of mitochondrial dynamic analysis, but this could be re-
lated to the different time-course expression between mRNA and protein.
Further investigation is needed to clarify the molecular biology of mito-
chondrial fission events.
CIDE proteins have a role in favoring LD fusion, but while CIDEC is
necessary to obtain one large LD, typical of white adipocytes, CIDEA alone
is not sufficient to induce an empowered LD fusion, hence it is associated to
a multilocular phenotype [95]. CIDE protein-coding genes Cidea and Cidec
show an expression pattern coherent with a multilocular phenotype, since
Cidea is significantly up-regulated in BDNF-treated cells after 3 hours of
incubation. Despite no significant differences have been recorded in Cidec
expression among samples, its mRNA levels decrease quite linearly from
CTRL to BDNF_24h. This pattern could be associated to a decline in LD
fusion. It has been in fact observed an increase in Cidea mRNA in cold-
exposed mice and NE-treated adipocytes [92]. The level of Plin1 clearly
reflects the pattern observed in Cidec expression. This may be because
CIDEC and PLIN1 narrowly cooperate in promoting the unilocular pheno-
type [96], so their simultaneous down-regulation could reflect a decrease
in LD fusion in favor of a multilocular phenotype. These results should be
implemented and supported by LD morphological studies as performed in
[99, 162].
The expression of Bdnf in BDNF-treated cells increased, especially after
three hours of incubation. This positive feedback loop has been described
to occur in microglia [182], hippocampal neurons and cortical neurons and
this feedback seems to be mediated by a TrkB-C/EBPβ signaling pathway
[183, 184]. This loop may occur in these cell types to prolong their acti-
vation under proper stimulation [182] and to improve their physiological
outcome, such as the consolidation of memory [183]. At the best of our
knowledge, this is the first time that this feedback loop has been detected
in adipose cells, but further research is needed to clarify the molecular biol-
ogy underneath this feedback, as the TrkB expression has not been inves-
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tigated in cultured adipocytes, although its presence has been confirmed in
adipocytes by Colitti et al. [185]. Likely, the effects of the loop detected in
the present research include the persistance of the brite phenotype.
The analysis of modifications in mitochondrial dynamic show a treatment-
dependent variation in their morphology: 3T3-L1 cells treated with BDNF
for 24 hours show the most significant change of mitochondrial structures,
being their profile quite similar to positive control cells. Indeed, the anal-
ysis of mitochondrial number, area surface and elongation confirmed the
onset of mitochondrial fission after BDNF incubation. This is particularly
evident after 24 hours-treatment, where cells displayed a reduction of the
number of branched tubular mitochondria flanked by an increase of small
globules. These features are in agreement with the onset of mitochondrial
fission, considering also the increase of simple tubules, that can derive from
the fragmentation of branched tubules [141]. Nevertheless, these results
are produced by a snapshot of a moment in cell life. Hence, they can be
corroborated by a time-lapse imaging of mitochondrial dynamic following
BDNF treatment to appreciate in real time the evolving structure of mito-
chondria.
Taken together, these results show that BDNF has a role in elevating
brown adipose markers and in significantly modulate mitochondrial mor-
phology in a time-dependent manner.
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Chapter 15
Retinoic acid as a browning
agent
15.1 Introduction
Carotenoids are a class of pigments present in many dietary sources.
They are precursors of retinoids, a set of bioactive molecules related to vi-
tamin A [186]. The most abundant carotenoid in human diet is β-carotene,
which can be metabolized by human tissues through the action of β-carotene-
15,15’-oxygenase 1 (BCO1). This enzyme cleaves β-carotene into two mol-
ecules of retinaldehyde (Rald), which can be ultimately oxidized to RA by
the action of aldehyde dehydrogenase [187].
In recent years, the involvement of carotenoids and, more importantly,
their metabolic products in regulating body fat mass and energy metabolism
has been confirmed [63]. The regulatory effects of retinoids in adipocytes
are primarily caused by their interaction with different kinds of nuclear re-
ceptors, namely canonical retinoic acid receptors (RARs) and retinoid X re-
ceptors (RXRs) [188], together with PPAR proteins. The most active agonist
ligands of these classes of receptors are the isomers of RA: all-trans retinoic
acid (atRA) and cis-9 retinoic acid (c9RA). atRA binds to RARs, while c9RA
binds to both RARs and RXRs. Activated RXRs form heterodimers with
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RARs, PPARs and other nuclear receptors to modulate gene expression in
adipocytes [189].
RA can induce Ucp1 expression, since the receptors heterodimers acti-
vated by RA isomers can bind to Ucp1 promoter [190]. Treatments with
atRA have been demonstrated to induce WAT browning and mitochondrial
biogenesis on animal models and in vitro cultures [191, 192]. Nevethe-
less, evidence of browning effect triggered by its isomer c9RA (see chemical
structure below) is still lacking.
OH
O
The present research aims to test the browning effect of c9RA on cul-
tured 3T3-L1 adipocytes by producing gene expression preliminary results
that will be implemented towards cytomorphological studies.
3T3-L1 culture was performed with conditions stated in Table 5.3. Con-
comitantly with the switch from differentiation to maintenance medium,
cells were treated with different concentrations of c9RA. A positive control
with 10 µM of isoproterenol, a selective β3-adrenergic agonist, has also been
established. A negative vehicle control was implemented by treating cells





To select the optimal dosage of c9RA, a cell viability test has been per-
formed with growing concentrations of the chemical. The tested doses were
0.5, 2, 10 and 20 µM. The viability of 3T3-L1 significantly diminished in a
dose-dependent manner, from around 90% of viable cells in the 0.5 µM dose
to less than 60% in the 20 µM one (Figure 15.1). According to this result,
the chosen doses for the subsequent experiments were 0.5 µM and 1 µM,
because the viability of 2 µM c9RA-treated cells was not acceptable.
Figure 15.1: Cell viability of 3T3-L1 cells treated with 0.5 (0.5RA), 2 (2RA), 10
(10RA) and 20 (20RA) µM c9RA. Data are expressed as the mean of
% viability relatively to negative control (CTRL) ± SEM. One-way
ANOVA with Bonferroni correction was used to detect significant
differences. Small letters indicate p < 0.05.
15.2.2 Gene expression analysis
All retinoid receptors increased their expression after the treatment of
cells with both 0.5 and 1 µM doses of c9RA (Figure 15.2, a). In detail,
Rara, Rxra (p < 0.05) and Rxrb (p < 0.01) were significantly up-regulated
compared to the positive control, while Rxra and Rxrb expression was sig-
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nificantly higher (p < 0.05) than the negative control in 3T3-L1 cells treated
with 0.5 µM c9RA. Rarb was significantly up-regulated (p < 0.05) in cells
treated with 1 µM c9RA. As expected, the expression of RA receptors in
isoproterenol-treated cells was not significantly different compared to the
negative control.
Figure 15.2: Relative fold change of retinoid receptors (a), browning markers (b)
and LD-associated genes (c). Data are expressed as the mean of
relative fold change ± SEM. One-way ANOVA with Bonferroni
correction was used to detect significant differences. *** p < 0.0001
vs CTRL; ** p < 0.01 vs CTRL; * p < 0.05 vs CTRL; §§§ p < 0.0001
vs ISO; §§ p < 0.01 vs ISO; § p < 0.05 vs ISO.
The browning markers Ucp1 and Tbx1 were significantly up-regulated
with the 0.5 µM dose of c9RA (Figure 15.2, b). Also Plin1 was significantly
up-regulated in c9RA-treated cells (Figure 15.2, b), but other LD-associated
genes and Lipe did not show any significant variation (Figure 15.2, c).
Interestingly, cells treated with isoproterenol did not produce a signif-
icant upregulation of browning markers. This is probably due to the fact
that cells were over-incubated with this molecule, which is known to pro-
duce effects after few hours following the administration, so the expression




To gain more information about the protein level of UCP1 and of PGC-
1α, a marker of mitochondrial biogenesis, ICW analysis was performed.
Since the administration of 0.5 µM c9RA produced the highest up-regulation
of browning markers, this analysis excluded the 1 µM dose. Figure 15.3
showed that the protein level of UCP1 was significantly low in ISO (p <
0.01) and in samples treated with 0.5 µM c9RA (p < 0.05). These data
could reflect on one side the lack of effectiveness of the treatment with iso-
proterenol, on the other side could mean that, in cells treated with c9RA,
the translation of mRNA into protein is not an immediate consequence of
the transcription of Ucp1 gene. Data about the PGC-1α show a clear up-
regulation of the protein in c9RA-treated cells with respect to both nega-
tive and positive controls (p < 0.05). This might lead to the assumption
that mitochondrial biogenesis is enhanced in c9RA-treated cells, but this
result needs to be corroborated by mitochondrial dynamic analysis and by
the analysis of Ppargc1a mRNA level.
Figure 15.3: Relative protein % from ICW analysis. Raw data were normalized
against the expression of α-tubulin, which served as housekeeping.
Data are expressed as the mean of relative fold change ± SEM.
One-way ANOVA with Tukey’s range test was used to detect
significant differences. ** p < 0.01 vs CTRL; * p < 0.05 vs CTRL; § p
< 0.05 vs ISO.
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15.3 Discussion
This preliminary study showed that the isomer of all-trans retinoic acid,
cis-9 retinoic acid, has a browning effect on 3T3-L1 adipocytes. RA has
been described as a factor promoting adipogenesis [193] and regulating
lipid metabolism [194], so it has been inferred its involvement in regulat-
ing WAT browning. The mechanism by which both isomers regulate Ucp1
expression involves their interaction with RAR and RXR nuclear receptors.
When activated, these receptors form heterodimers with each other and
also with other nuclear receptors, including PPARγ, to modulate the ex-
pression of Ucp1 and a number of other genes [195]. Nevertheless, recent
studies showed that atRA mediates mitochondrial biogenesis also through
an AMPK-dependent up-regulation of Ppargc1a gene [195]. This seems to
occur also with c9RA administration, as the protein level of PGC-1α in-
creased following the treatment. The administration of c9RA to 3T3-L1
up-regulates the expression of its nuclear receptor, in line with previous
results [196]. The up-regulation of Ucp1 and Tbx1 can indicate that a
brite phenotype has been established on treated cells, but further analy-
ses are needed to strengthen this observation. Recent findings highlighted
the involvement of lipocalin 2, a novel adipokine, in the regulation of atRA-
mediated browning [197], hence its role in mediating the cellular response
to c9RA deserves further elucidation.
Among genes associated in LD remodeling, those encoding for CIDE-
proteins did not show any significant variation, probably due to the high
level of individual variability. Nevertheless, Figure 15.2c showed that their
mRNA level is higher in cells treated with the two doses of c9RA, so this
might account for a dynamic remodeling of LDs. Morphological studies
on LDs are required to verify if c9RA triggers a LD remodeling towards
a multilocular phenotype, which has been observed as a typical feature of
browning white adipocytes [92]. The significant up-regulation of Plin1 has
a similar pattern to Lipe, so there might be a relation between these two
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proteins. Despite PLIN1 has a role in improving CIDEC’s functionality
during LD fusion, some findings indicate a role of phosphorylated PLIN1
in favoring a multilocular phenotype through its interaction with key LD-
remodeling proteins [198]. Moreover, it has been observed that PLIN1 can
promote Lipe expression [199] and that an up-regulation of Plin1 has a
protective effect against diet-induced obesity [200, 201].
Taken together, these preliminary data account for an involvement of





The results presented in this thesis demonstrated that analyzed bioac-
tive factors induced browning in different cellular models. This evaluation
has been performed through the analysis of the expression of browning
molecular markers and of structural modifications of lipid droplets and mi-
tochondria. The tested molecules displayed different degrees of browning
efficacy in function of their dose or the duration of the incubation period
through multiple pathways that should be deeper investigated. The knowl-
edge of the best combination of browning factor dose and time of exposure
will be of outstanding importance in transferring the results of this re-
search into clinical practice for the treatment of obesity and related co-
morbidities (i.e. type 2 diabetes mellitus), since prolonged exposure and
sub-optimal doses do not produce satisfactory outcomes in terms of thermo-
genic activation and reduction of adiposity. Research on bioactive molecules
can be translated in the realization of effective nutraceutical preparations
in support of traditional obesity treatments, while the study of endogenous
molecules may spread new light on the beneficial effect of physical exercise
and other positive behaviors on energy expenditure.
The results of this research improved our understanding of WAT brown-
ing, bringing novel knowledge about the expression of brown and brite
markers after prolonged treatments on fully differentiated adipocytes. For
the first time, new approaches to study browning induced by the selected
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compounds involved variations of LDs size and mitochondrial shape. Nev-
ertheless, trials with the selected or other compounds could deeper analyze
the molecular pathways that lead to the phenotypic conversion in treated
cells, i.e. with gene silencing experiments, inhibition of target receptors or
proteins involved in the signal transduction and transcriptomic analyses.
Moreover, morphological variations were highly descriptive and useful
to outline phenotypic changes and can be improved with time-lapse exper-
iments to exploit time-course modifications and with electron microscopy
to depict ultrastructural changes. Moreover, these experiments will be re-
peated on immortalized murine brown adipocytes (IMBAT cells) to streng-
then the results.
Most importantly, this thesis evidenced that browning of WAT is not
just an increase of UCP1 content, as many other factors participate to the
onset of a thermogenic response and this response varies among different
types of cell. Hence, to produce significant results that could be translated
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Obesity is the result of energy intake chronically exceeding energy expenditure.
Classical treatments against obesity do not provide a satisfactory long-term out-
come for the majority of patients. After the demonstration of functional brown ad-
ipose tissue in human adults, great effort is being devoted to develop therapies
based on the adipose tissue itself, through the conversion of fat-accumulating white
adipose tissue into energy-dissipating brown adipose tissue. Anti-obesity treatments
that exploit endogenous, pharmacological and nutritional factors to drive such
conversion are especially in demand. In the present review, we summarize the cur-
rent knowledge about the various molecules that can be applied in promoting
white-to-brown adipose tissue conversion and energy expenditure and the cellular
mechanisms involved.
Keywords: Brown adipose tissue, browning, thermogenesis, white adipose tissue.
Abbreviations: 5-HT, serotonin; 5-HT1B, serotonin receptor 1B; 5-HT2C, seroto-
nin receptor 2C; β3-ARs, β3-adrenergic receptors; AC, adenylyl cylcase; AMPK,
cAMP-activated protein kinase; AR, adrenoreceptor; AT, adipose tissue; atRA,
all-trans retinoic acid; BAIBA, β-aminoisobutyric acid; BAT, brown adipose tissue;
BC, β-carotene; BCO1, β-carotene-15,150-oxygenase; BCO2, β-carotene-90,100-ox-
ygenase; BMP, bone morphogenetic protein; BNP, brain natriuretic peptide; cAMP,
cyclic adenosine monophosphate; CLA, conjugated linoleic acid; COX, cyclooxy-
genase; DIO2, type II iodothyronine 50-deiodinase; DMH, dorsomedial hypothala-
mus; FA, fatty acid; FGF21, fibroblast growth factor 21; FNDC5, fibronectin type
III domain-containing protein 5; FX, fucoxanthin; Gs, stimulatory G protein; HFD,
high fat diet; IL, interleukin; MAPK, mitogen-activated protein kinase; MT, mela-
tonin receptor; Myf5, myogenic factor 5; NE, norepinephrine; OX, orexin; PG,
prostaglandin; PGC-1α, PPARγ coactivator-1α; PKA, protein kinase A; PPAR, per-
oxisome proliferator-activated receptor; PRDM16, PR/SET domain 16; PUFA,
polyunsaturated fatty acid; Rald, retinaldehyde; RAR, retinoic acid receptor;
RXR, retinoid X receptor; SA, synephrine alkaloid; SIRT1, silent information reg-
ulator type 1; T3, triiodothyronine; T4, thyroxine; TR, thyroid hormone receptor;
TRPM8, transient receptor potential cation channel subfamily M, member 8;
TRPV1, transient receptor potential cation channel, subfamily V, member 1; TX,
thromboxane; UCP1, uncoupling protein 1; VMH, ventromedial hypothalamus;
WAT, white adipose tissue.
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Introduction
Adipose tissue (AT) is the main form of storage of excess en-
ergy intake derived from food. This feature guarantees the
survival of an organism even during long fasting periods.
Nowadays, food availability to mankind is far greater than
in past centuries; thus, dietary habits dramatically changed
all over the world. This has led to the epidemic diffusion
of obesity in last decades, with the highest number of cases
being recorded in western countries (i.e. Europe and USA).
Today, this problem has reached devastating proportions,
as obese patients are growing in number also in developing
countries. According to recent data published by the World
Health Organization (1), 1.9 billion adults (39%) are over-
weight (body mass index ≥25 kg m2) and 600 million indi-
viduals (13%) are obese (body mass index ≥30 kg m2).
This health issue is not gender-specific, as 38% of men
and 40% of women are overweight and 11% of men and
15% of women are obese. Moreover, great concern is grow-
ing from the diffusion of child obesity, as over 41 million
children are overweight before reaching puberty (1).
Obesity is a serious risk factor as it is associated with met-
abolic syndrome (2), a cluster of morbidities that includes
type 2 diabetes mellitus (3,4), cardiovascular disease, in-
cluding hypertension (5) and chronic kidney disease. More-
over, obese patients are more prone to contract several
forms of cancer with reduced chances of survival (6).
In light of these facts, it is of primary importance to find
more effective approaches to treat obesity. The traditional ap-
proachthat involves themodificationofdietaryhabitsandthe
increase of physical activity often is not effective, as often the
fatmass loss is only transient and the regainofbodyweight af-
ter a long period of diet and exercise is very common (7). On
the other hand, the bariatric surgery, which could be an effec-
tive alternative, is not viable in all cases. After the discovery of
functional brown adipose tissue (BAT) masses in human
adults through several combined imaging techniques (8,9),
there is a growing interest in finding therapies for obesity that
start from the AT itself, as the conversion of fat-accumulating
white adipose tissue (WAT) into energy-dissipating BATmay
be an effective and potentially harmless solution.
This review has the purpose to illustrate the current find-
ings about all factors and natural compounds that have
been studied in recent years, classifying them as endoge-
nous, pharmacological and nutritional factors. In order to
explain the potential efficiency of these agents in WAT to
BAT conversion, their biochemical and molecular mecha-
nisms are also elucidated.
Conversion of white adipocytes into brown-like
adipocytes
The biology and developmental origins of BAT and the dif-
ferences between WAT and BAT have been clearly and
deeply reviewed in the past years (10–13). BAT has become
central in research on obesity because of adaptive thermo-
genesis, i.e. the process of regulated heat production that
is in part mediated by the catabolism of energy substrates
without the release of chemical energy from the breakdown
of adenosine triphosphate. This process is led by uncoupling
protein 1 (UCP1), a transmembrane protein present in the
inner mitochondrial membrane of mitochondria in brown
adipocytes. UCP1 participates in adaptive thermogenesis
by uncoupling the production of adenosine triphosphate
from the catabolic pathways of lipids and carbohydrates.
The derived energy is released by the brown adipocytes in
form of heat that diffuses in the body, thanks to the rich vas-
cularization of BAT.
Uncoupling protein 1 is uniquely expressed in BAT; thus,
an increase in BAT mass in obese patients may improve en-
ergy dissipation. One of the possible ways to increase the
presence of functional UCP1-rich cells in AT is the conver-
sion of white (pre)adipocytes into brown-like fat cells,
known as WAT browning. The result is the appearance in
WAT of dispersed masses of brown-like adipocytes, named
beige or brite (brown-in-white) adipocytes. These cells share
a number of characteristics with brown adipocytes, as they
show a multilocularized accumulation of fat reserves, are
rich in mitochondria and express high levels of UCP1 and
factors that increase the transcription of key proteins of
thermogenesis, (e.g. members of the peroxisome
proliferator-activated receptor (PPAR) family, cell death-
inducing DFFA-like effector A, PR domain containing 16
(PRDM16) and others reviewed in (ref. (11)). Brite adi-
pocytes show, nevertheless, a unique gene expression
profile, which is different from both white and brown
adipocytes (14–16). Browning is not the only way to
obtain brite adipocytes: other developmental pathways,
e.g. differentiation from Myh11+ smooth muscle
precursor cells or from mesodermal stem cells-derived
preadipocytes are involved (17).
White adipose tissue browning is mainly driven by sym-
pathetic stimulation and by the interaction of norepineph-
rine (NE) with β3-adrenergic receptors (β3-ARs) present on
the plasma membrane of white adipocytes. Such an interac-
tion starts a signal transduction cascade that ends in the
overexpression of UCP1 and other thermogenic proteins.
A number of studies and observations confirmed the fact
that, endogenously, the mechanisms that drive classic BAT
recruitment and WAT browning are the same (18), while
the administration of exogenous molecules may selectively
activate BAT thermogenesis or recruit brite adipocytes.
Chronic cold exposure is the most effective sympathetic
activator (18), as it induces a massive thermogenic response
in WAT. Exposure to cold is quite unsuitable and uncom-
fortable for obese patients; hence, other so-called “brow-
ning agents” have been investigated in the last years. Here
follows a description of the most relevant and promising
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endogenous, pharmacological and nutritional browning
factors and their cellular pathways.
Endogenous browning factors
Norepinephrine and central sympathetic activators
As previously mentioned, the expression of UCP1 is under
adrenergic control: the activation of β3-ARs by NE triggers
a signal transduction cascade that involves a number of en-
zymes and transcription factors that, either directly or indi-
rectly, affect the expression level of UCP1 (19). The
interaction of NE with β3-ARs causes the activation of a
linked stimulatory G protein (Gs) that, in turn, activates
the membrane enzyme adenylyl cylcase (AC). AC stimulates
the production of cyclic adenosine monophosphate (cAMP),
which is the necessary activator of protein kinase A (PKA).
This is a key enzyme in NE stimulation; therefore, the
sympathetic-mediated adaptive thermogenesis is known as
a cAMP/PKA-dependent process. The PKA-dependent
transduction pathways that lead to the overexpression of
UCP1 are (i) p38 mitogen-activated protein kinase (MAPK),
which stimulates the expression of the PPARγ coactivator-
1α (PGC-1α) and the activating transcription factor 2, that
are directly involved in the overexpression of UCP1; (ii)
cAMP response element binding protein, which directly
binds on UCP1 promoter in a p38 MAPK-independent
manner (10,19); (iii) the Janus kinase/signal transducer
and activator of transcription pathway, which mediates
thermogenesis by transducing the signal of several
adipose-affecting substances (20); (iv) the silent information
regulator type 1 (SIRT1), which amplifies adrenergic re-
sponse and stimulates PGC-1α (21). These pathways are
also involved in the mitochondrial biogenesis, which is fun-
damental in reaching a brown-like phenotype.
The peripheral release of NE is centrally regulated by a
number of proteins produced either by the central nervous
system itself or by other peripheral tissues. Leptin is an
adipokine whose release is proportional to AT mass, and it
has a role in the regulation of food intake and regulation
of metabolism (22). Receptors for leptin are centrally lo-
cated mainly in the arcuate and in the ventromedial
(VMH) nuclei of hypothalamus. Recently, leptin receptors
involved in the stimulation of thermogenesis were also
found in dorsomedial hypothalamus (DMH) (23). Sympa-
thetic stimulation driven by leptin is mediated by the
melanocortin system via the release of the α-melanocyte-
stimulating hormone, which interacts with the
melanocortin-4 receptor. The activation of this receptor
causes a production of corticotropin-releasing hormone that
finally activates the peripheral release of NE (24). In the ad-
ipocyte, leptin positively regulates the expression of β3-ARs,
and in vitro studies demonstrated that leptin can stimulate
the expression of PGC-1α and the peroxisome proliferator-
activated receptor α (PPARα) (25–27). PPARα is another
key transcription factor involved in the expression of
UCP1 and other genes linked to thermogenesis (28).
The neuropeptide VGF nerve growth factor inducible is
engaged in energy homeostasis, and its proteolytic cleavage
produces a number of bioactive polypeptides. Among these,
TLQP-21 was shown to centrally activate the release of NE,
and, consequently, its effects include the overexpression of
UCP1 in WAT and the reduction of fat mass following a
high fat diet (HFD) in rats (29). Similarly, the brain-derived
neurotrophic factor modulates the sympathetic activity
leading to WAT browning in response to environmental
cues, such as cold exposure and enriched environments
(30). Afterwards, it has been demonstrated that the central
activity of brain-derived neurotrophic factor is peripherally
mediated by the fat depot-specific expression of the vascular
endothelial growth factor (31), which has also a role in
angiogenesis of BAT and brown-like AT (32).
Myokines
Myokines are endocrine mediators produced by skeletal
muscles. They are usually released during the contraction
of muscle fibers and link the physical exercise to the loss
of fat mass (33).
Irisin is a PGC-1α-dependent myokine that derives from a
specific proteolytic cleavage of the fibronectin type III
domain-containing protein 5 (FNDC5). Its anti-obesity ef-
fect is mediated through the expression of genes linked to
lipid catabolism and uncoupling process (including UCP1)
selectively in WAT depots, mainly subcutaneous ones (33).
AT FNDC5 mRNA and irisin levels in circulation are nega-
tively associated to type 2 diabetes mellitus, leptin and
myostatin and positively related to the muscle mass (34).
Irisin is recognized as a powerful myokine inducing WAT
browning in many animal models. A recent study on human
adipocytes showed that irisin acts via the stimulation of p38
MAPK pathway and positively autoregulates adipocyte
FNDC5 expression (35).
The β-aminoisobutyric acid (BAIBA) is again a PGC-1α-
mediated and exercise-triggered, non-adrenergic activator
of WAT browning. This myokine, a metabolite of valine
and thymine metabolism, is released during muscle contrac-
tion. In animal models, it was demonstrated that BAIBA is a
strong stimulator of the mitochondrial activity and en-
hances the expression of BAT-related genes in white adipo-
cytes, via a PPARα-dependent mechanism. Through the
same mechanism, BAIBA improves the lipolytic catabolism
in liver, by increasing the expression of specific enzymes in-
volved in β-oxidation (36–38).
Meteorin-like protein is a myokine having an indirect ac-
tion on WAT browning. Circulating meteorin-like protein
can activate eosinophils in WAT to produce interleukin-4
(IL4) and IL13 with a browning effect (39).
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Interleukin-6 can be also considered as a myokine be-
cause it is markedly released by skeletal muscle during exer-
cise. Daily intramuscular injections of IL6 in mice showed
to raise UCP1 expression levels in WAT (40).
Thyroid hormones
The regulation of UCP1 synthesis, mediated by thyroid hor-
mones, is independent of adrenergic stimulation, and these
two pathways cooperate in a synergistic way (41). Triiodo-
thyronine (T3) is the hormone that actively and directly reg-
ulates UCP1 expression. It is mainly released by the thyroid
gland, but the adipocyte itself is able to catalyze the conver-
sion of thyroxine (T4) to T3 by the enzyme type II
iodothyronine 50-deiodinase (DIO2). The enzyme DIO2 is
activated by adrenergic stimulation and is strongly inhibited
by its own substrate, T4 (42).
The adipocyte has two nuclear receptors for T3, the thy-
roid hormone receptor α (TRα) and TRβ. The latter stimu-
lates UCP1 expression (13) that is proportional to T3
concentration in AT. The distal enhancer of UCP1 contains
the thyroid response element with the binding site for the
T3/thyroid hormone receptor β complex. T3, as a sympa-
thetic activator, induces UCP1 expression at central level,
too (43).
Fibroblast growth factor 21
The fibroblast growth factor 21 (FGF21) is an endocrine
factor involved in the regulation of hepatic lipid metabo-
lism, glycaemia and the functionality of pancreatic β-cells,
and it is mainly produced by liver (44). In adipose cells
FGF21 interacts with the FGF receptor and its co-receptor
β-Klotho. The activated receptor triggers the p38 MAPK
pathway that in turn stimulates UCP1 expression inducing
both BAT activity and WAT browning (45). Notably, ther-
mogenic activation induces FGF21 release by brown adipo-
cytes (but not by white ones), thus exerting an autocrine
effect on the brown fat cell (46). Thus while hepatic
FGF21 triggers thermogenesis in BAT and induces WAT
browning with an endocrine mechanism, adipose FGF21
sustains the progression of the thermogenesis itself in brown
and brite adipocytes with an autocrine mechanism.
It is important to notice that in obese patients, FGF21 sig-
nalling is impaired by the pro-inflammatory environment
established inWATmasses, because increased tumour necro-
sis factor α develops an FGF21-resistant phenotype by inter-
fering with the expression of β-Klotho co-receptor (47,48).
Bone morphogenetic proteins
Proteins belonging to this family are involved in normal
BAT development and in WAT browning. The bone mor-
phogenetic protein 7 (BMP7) is a key factor in brown
adipocyte differentiation as it participates in programming
of Myf5+ precursor cells towards a BAT phenotype (49).
BMP7 stimulates the expression of early BAT regulator
PRDM16 and PGC-1α, thus the synthesis of UCP1. Accord-
ing to a recent study, BMP7 is able to recruit UCP1-rich and
mitochondria-rich brite adipocytes from both human
adipose-derived stem cells and white adipocytes (50).
Another member of the number 7 morphogenetic pro-
teins family, BMP8B, is not a browning agent at a peripheral
level but is crucial in maintaining the thermogenic process in
BAT. It is able to improve NE response in brown adipocytes
enhancing the p38 MAPK/cAMP response element binding
protein pathway for UCP1 expression (51). At a central
level, the thermogenic effect of BMP8B in both BAT and
WAT is sexually dimorphic: it is observed only in females
as it is dependent on ovarian estradiol levels (52). The
thermogenic effect of BMP8B is achieved by the regulation
of hypothalamic cAMP-activated protein kinase (AMPK)
in VMH, with peripheral consequences on BAT activation
and WAT browning (53). Moreover, central BMP8B in-
creases orexin (OX) release in the lateral hypothalamic area
through a glutamatergic signalling (53). The key role of OX
in BAT activity will be discussed in the next sections.
BMP4 was believed to uniquely induce lipid accumula-
tion and differentiation of white adipocytes (54). Several re-
cent studies suggest a possible role of BMP4 in WAT
browning, even though such role is still controversial. Xue
et al. (55) assume that BMP4 induces PGC-1α expression
in white preadipocytes and cultured stem cells, leading to
the development of brite adipocytes with a strong increase
of brite markers expression and biogenesis of mitochondria.
This mechanism is supported by further research (56,57). A
more recent study demonstrates an opposite role for BMP4
as an inducer of the switch from a brown phenotype to a
white-like one (58).
Cardiac natriuretic peptides
Recently, cardiac natriuretic peptides have been recognized
as metabolic hormones with a role in regulation of fat mobi-
lization during physical exercise, in fat oxidation by skeletal
muscles and browning of white adipocytes. Three peptides
belong to this family: atrial natriuretic peptide, brain natri-
uretic peptide (BNP) and C-type natriuretic peptide (59).
They are produced by the heart and target a number of or-
gans, including WAT and BAT. Atrial natriuretic peptide
and BNP achieve their biological effects through the natri-
uretic peptide receptor A, while C-type natriuretic peptide
preferentially binds to NPRB. They are both guanylyl
ciclase receptors. In WAT, natriuretic peptide (NP) signalling
stimulates lipolytic pathways via activation of a cyclic
guanosine monophosphate-regulated protein kinase, which
in turn phosphorylates hormone-sensitive lipase and
perilipin (60).
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Cold exposure promotes the secretion of BNP and the
synthesis of natriuretic peptide receptor A: activated cyclic
guanosine monophosphate-regulated protein kinase in adi-
pocytes stimulates the p38 MAPK pathway, increasing the
synthesis of UCP1 and thus triggering the browning pro-
cess. The NP-mediated browning pathway is independent
from NE stimulation, and the effects are more likely addi-
tive (61).
Adipokines
Besides leptin – discussed previously – some other
adipokines can participate into the browning process of
WAT. Cold exposure strongly raises the production of
adiponectin in subcutaneous WAT. A study on mice shows
that the increased circulating adiponectin recruits beige adi-
pocyte through the increase of resident M2 macrophages in
the stromal vascular fraction of subcutaneous WAT,
strongly highlighting a link between immunity and WAT
browning (62).
Apelin concentration in plasma increases with obesity
and hyperinsulinaemia (63). In the adipocyte, apelin
triggers a brite phenotype by increasing the expression
of UCP1 gene and its transcription factors affecting
phosphoinositide 3-kinase/protein kinase B and AMPK
pathways (64). However, it has been demonstrated that
chronic intracerebroventricular infusion of apelin in mice
depresses energy expenditure and BAT functionality,
contributing to the development of obesity and related
morbidities (65).
Lipid mediators
The role of WAT in the production of both pro-
inflammatory and anti-inflammatory lipid mediators, i.e.
prostaglandins, thromboxanes, and leukotrienes, was
investigated by Garcia-Alonso et al. (66). According to
the current understanding, arachidonic acid is oxygenated
by the isoforms of the enzyme cyclooxygenase (COX) to
release prostaglandins and thromboxanes and by
lipooxygenase to synthesize leukotrienes. The coordinated
activity of enzymes COX-2 and microsomal PGE
synthase-1 leads to the synthesis of PGE2, which stimulates
the differentiation, towards a brown-like phenotype, of
white preadipocytes. This is possibly achieved through a
cAMP-dependent and PPARγ-dependent mechanism,
because PGE2 and some related compounds are agonist
ligands of PPARγ isoforms (67). The evidence of a link
between WAT browning and COX-2 overexpression is pro-
vided in a previous study (68). A more recent research, on
the other hand, shows that an excess of PGE2 and PGF2α,
accumulated by a marked increase in dietary arachidonic
acid, inhibits the white-to-brown conversion pathway by
decreasing UCP1 expression in a Ca2+-regulated and
extracellular signal-regulated kinase pathway-dependent
fashion, but without negative consequences on
mitochondriogenesis (69). PGE2 affects brown thermogene-
sis also by mediating the activity of CC chemokine ligand
22, a pyrogenic cytokine that binds to the CC chemokine
receptor 4 in the anterior hypothalamus/pre-optic area.
This area of the nervous system is functionally linked to
thermogenic tissues, including BAT; hence, the hyperther-
mic effect of CC chemokine ligand 22 is carried out by a
change in the metabolic rate of BAT (70).
A recent study highlights the browning potential of
another metabolite of arachidonic acid, i.e. prostacyclin.
In vitro treatment of human multipotent adipose-derived
stem cell cultures with prostacyclin’s analogue
carbaprostacyclin induces the development of functional
brite adipocytes through the functional coupling between
membrane receptor IP-R and Gs protein, thus using the
cAMP-dependent pathway in activating AC (71). This lipid
mediator produces an amplified effect thanks to its ability to
agonistically bind to PPARγ isoforms that are promoters of
both, adipogenesis and UCP1 synthesis (66,71).
Serotonin
Serotonin (5-HT) is a monoamine with a number of func-
tions both, at central and at peripheral level, including reg-
ulation of appetite and energy homeostasis. Central 5-HT
has an anorexigenic effect because 5-HT modulates the hy-
pothalamic feeding circuit (which involves some of the
hypothalamic nuclei already mentioned) through the activa-
tion of receptors 5-HT1B and 5-HT2C (72). 5-HT can also
affect BAT metabolism in the hypothalamus, because
neurons of DMH are synaptically linked to the raphe
pallidus, which modulates sympathetic activation through
a serotoninergic circuit. In mice, this circuit promotes ther-
mogenesis when cholinergic muscarinic receptors linking
DMH to raphe pallidus are antagonized (73). Moreover,
the depletion of serotoninergic neurons in mice produces
severe impairments in glucose and lipid metabolisms and
in brown and brite adipocyte’s thermogenic capacities
(74). Hence, central serotoninergic regulation is funda-
mental in the control of both, appetite and energy
homeostasis.
At a peripheral level, the major source of 5-HT is gut, and
AT represents a target, as 5-HT regulates many functions
related to adipogenesis and energy metabolism. In AT
itself, 5-HT was found to be an obesogenic factor that
promotes lipid accumulation in WAT and inhibits WAT
browning and BAT thermogenesis. A study performed on
mice demonstrated that the inhibition of tryptophan
hydroxylase 1, the enzyme responsible for peripheral 5-
HT synthesis, induced lean phenotypes with activated
BAT and recruited brite adipocytes (75).
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Other endogenous factors
Adenosine plays a dual role in AT: in WAT, it inhibits lipol-
ysis, while in BAT, it increases it. It is likely that the different
adenosine receptors present in the two cell types trigger dif-
ferent effects. In white adipocytes, there is a high abundance
of A1 receptor, while in brown adipocytes, the Gs-coupled
A2a type (adenosine receptor 2a) is the most present.
Adenosine released from sympathetic nerves and from
the adipocyte itself, following adrenergic stimulation, in-
creases the synthesis of UCP1 through a cAMP-dependent
pathway (76,77). A proper pharmacological stimulation of
adenosine receptor 2a with agonists can induce browning
in WAT.
The appetite-inducing neuropeptide OX is produced in
lateral hypothalamic area and has a fundamental role in me-
diating the differentiation of mature brown adipocytes and
in promoting thermogenesis and uncoupled metabolism.
OX-null mice displayed a lack of mature, thermogenically
active brown adipocytes and an abundance of
preadipocytes unable to accumulate lipid droplets and to
perform thermogenesis (78). As previously mentioned, the
presence of a sustained OX signalling is also fundamental
for the mediation of BMP8B effects on BAT functionality
(53). Effects of OX on BAT are achieved through its interac-
tion with OX receptor-1 (79).
Melatonin is a hormone acting as an autocrine/paracrine
factor. It is secreted by many tissues and organs, but the
main melatonin source is the pineal gland. The synthesis
of melatonin by the pineal gland is regulated by the hypo-
thalamic paraventricular nucleus and is triggered by the re-
lease of NE in specific ganglia. This activation is further
regulated by the suprachiasmatic nucleus of the hypothala-
mus (80). Physiological effects of melatonin are driven by
melatonin receptors MT1, MT2 and MT3, even if
receptor-independent actions of melatonin are possible,
and they concern the scavenging of free radicals (80).
Melatonin regulation of energy metabolism involves the
circadian distribution of different metabolic processes
(81), the control of insulin synthesis and effectiveness
(82,83) and the regulation of AT energy metabolism. In
this respect, recent findings evidence that long-term
pinealectomized rats are overweight, diabetic and with
impaired AT physiology, but normal conditions are re-
stored by daily melatonin supplementation (80). In nor-
mal animals, the supplementation with melatonin is
shown to reduce body weight and abdominal fat mass
through activation of BAT and browning of WAT (84).
Moreover, chronic administration of melatonin also re-
duces ageing-related loss of insulin sensitivity in rats
(85). Taken together, these findings highlight the thera-
peutic potential of melatonin against obesity and insulin
resistance.
All endogenous browning factors are summarized in
Fig. 1 and Table 1.
Figure 1 Endogenous factors (orange squares) involved in white adipose tissue browning and their cellular targets (blue circles). Receptors are reported
in red boxes. The pathways that directly participate to upregulation of UCP1 (yellow circle) are reported along the brown arrow. All orange arrows indicate a
stimulatory effect. 5-HT, serotonin; A2aR, adenosine receptor 2a; AMPK, cAMP-activated protein kinase; APJ, apelin receptor; BAIBA, β-aminoisobutyric
acid; BDNF, brain-derived neurotrophic factor; BMP, bone morphogenetic protein; BNP, brain natriuretic peptide; DIO2, type II iodothyronine 50-
deiodinase; FGF21, fibroblast growth factor 21; IL, interleukin; NPRA, natriuretic peptide receptor A; OX, orexin; p38 MAPK, p38 mitogen-activated pro-
tein kinase; PGC-1α, PPARγ coactivator-1α; PKA, protein kinase A; PPAR, peroxisome proliferator-activated receptor; T3, triiodothyronine; T4, thyroxine;
TRβ, thyroid hormone receptor β; UCP1, uncoupling protein 1; VEGF, vascular endothelial growth factor. [Colour figure can be viewed at
wileyonlinelibrary.com]
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Table 1 Endogenous factors involved in BAT development and recruitment, WAT browning and UCP1 upregulation
Browning factors Cellular
target
Mechanisms of action Effect Ref.
Norepinephrine β3-AR Activation of cAMP/PKA-dependent signalling pathways Upregulation of UCP1 10
Leptin ObR Inhibition of orexigenic NPY/AgRP neurons and stimulation of anorexigenic POMC/CART
neurons
Suppression of appetite 22,23,25–27
Stimulation of melanocortin/corticotropin system Increase of noradrenergic stimulation of BAT and WAT
Upregulation of β3-AR, p38 MAPK and PGC-1α
? Activation of JAK/STAT signalling pathway Stimulation of WAT lipolysis.
Upregulation of ACO, CPT1 and PPARα
TLQP-21 ? Central, prostaglandin-dependent stimulation of adrenal medulla Increase of epinephrine and upregulation of β2-AR in BAT 29
Upregulation of β3-AR, PPARδ and UCP1 in WAT
BDNF TrkB Early regulation of hypothalamic activity Increase of sympathetic output 30,31
Upregulation of adipose VEGF
Irisin ? Stimulation of p38 MAPK signalling pathway and positive autoregulation of FNDC5
expression
Upregulation of UCP1 33,35
Stimulation of lipid catabolism
BAIBA PPARα Regulation of gene expression Upregulation of PPARα and UCP1 37
Increase of FA oxidation
Meteorin-like ? Recruitment of eosinophils and alternative activation of macrophages Indirect WAT browning through IL4 and IL13 signalling 39
Interleukin 6 IL6R PGC-1α-dependent modulation of gene expression Upregulation of UCP1 40
Triiodothyronine TRβ Bond of activated TRβ to UCP1 distal enhancer Upregulation of UCP1 41
Thyroxine DIO2 Intracellular conversion to triiodothyronine Upregulation of UCP1 42
FGF21 FGFR, Stimulation of p38-MAPK. Autocrine effect on brown adipocytes Upregulation of UCP1 45,46
β-Klotho
BMP7 BMPR1 Early brown adipocyte programming of Myf5
+
progenitor cells Differentiation of brown adipocytes 49
BMPR2 Promotion of the expression of brown and brite fat gene markers Differentiation of brite adipocytes from not fully differentiated white
fat cells
50
BMP8B BMPR1A Stimulation of p38 MAPK/CREB signalling pathway in brown adipocytes Maintenance of the thermogenic machinery, upregulation of
orexin synthesis
51,53
Central, estradiol-dependent stimulation of hypothalamic nuclei, in opposition to AMPK and
increase of sympathetic tone
BMP4 BMPR1 Stimulation of p38 MAPK/PGC-1α/ATF2 signalling pathway Upregulation of glucose and lipid metabolism, expression of brite
phenotype in differentiating adipocytes
56,57
BMPR2
ANP and BNP NPRA cGMP/PKG-dependent stimulation of p38 MAPK/PGC-1α signalling pathway Upregulation of UCP1 and increase of lipolysis 59,60
Adiponectin adipoR1 Promotion of polarization and maintenance of resident M2 macrophages after cold-exposure scWAT browning 62
adipoR2
Apelin APJ Activation of PI3K/Akt and AMPK signalling pathways in brown adipocytes. Autocrine
positive feedback
Brown adipogenesis, upregulation of UCP1 64
Stimulation of AMPK signalling pathway and upregulation of PRDM16 in white adipocytes WAT browning, inhibition of adipogenesis
Prostaglandin E2 EP4 Modulation of cAMP level in the adipocyte Increased lipolysis 66
Stabilization of white-to-brown transcriptional regulators Promotion of WAT browning
PPARγ Interaction with PPARγ Upregulation of UCP1
Carbaprostacyclin IP-R Activation of cAMP/PKA-dependent signalling pathway Upregulation of UCP1 and WAT browning 71
PPARγ Interaction with PPARγ




































































































The β3-AR is an atypical adrenoreceptor found in AT (10).
Hence, the selective stimulation of this receptor may drive
BAT activation and WAT browning with light or absent car-
diovascular side effects, which are reported for non-selective
sympathomimetic drugs. A number of molecules underwent
clinical trials, but the majority was rejected at the clinical
phase II because of lack of efficacy in human β3-AR (86).
L-796568 was among the first β3 agonists with docu-
mented increased energy expenditure in humans (87). Tests
on humans accounted for acute increase (8%) of energy
expenditure in obese patients (88), but chronic effects
were not observed (89). This drug produced no cardiovas-
cular side effects, as the bond with β1-AR and β2-AR did
not occur.
Mirabegron is a recently discovered β3 agonist which pro-
duces a marked increase in resting metabolic rate (13%) in
young male, suggesting a powerful activation of BAT ther-
mogenesis (90,91). This is a promising anti-obesity drug,
despite cardiovascular side effects due to its weak affinity
to other β-ARs.
Drugs affecting the serotoninergic system
As previously discussed, central 5-HT is an important factor
in stimulating thermogenesis and recruiting brite adipo-
cytes; hence, drugs affecting the central serotoninergic cir-
cuit may increase the 5-HT-mediated actions on AT.
Selective serotonin re-uptake inhibitors are classically
used as antidepressant drugs, but they can also find inter-
esting applications in obesity treatment. Sibutramine is a
drug that inhibits the re-uptake of both 5-HT and NE in
central synapses; it is converted in two active metabolites
that achieve the anti-obesity effect by reducing appetite
and increasing thermogenesis (92). Chronic treatment
with sibutramine also improves biochemical blood param-
eters associated with obesity and diabetes: glycaemia,
insulinaemia, triglycerides, total cholesterol, low-density
lipoprotein cholesterol, high-density lipoprotein choles-
terol and glycosylated haemoglobin (92,93). Side effects
include severe cardiovascular outcomes, like increase in
heart rate and blood pressure and in the likelihood of
non-fatal myocardial infarction or stroke. For this reason,
the drug was not eligible for patients with a history of
cardiovascular disease, and it has been withdrawn from
the market (94).
Fluoxetine is another member of selective serotonin re-
uptake inhibitor class of pharmaceuticals. A recent study
performed on rats shows that chronic fluoxetine adminis-
tration reduces body mass and WAT mass without affecting
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in BAT mass, UCP1 expression and mitochondria metabolic
rate, measured as O2 consumption (95).
Fenfluramine and its d-isomer, dexfenfluramine, are sero-
toninergic drugs that suppress appetite by increasing the
synaptic release of 5-HT. Like sibutramine, these molecules
produce serious side effects, including heart valve damages
and pulmonary arterial hypertension (96). The association
with other drugs, like phentermine (a centrally active, nor-
adrenergic drug) attenuates the side effects (97). Neverthe-
less, both fenfluramine and dexfenfluramine were
withdrawn from the market (94).
Tamoxifen
The modulator of oestrogen receptor tamoxifen is currently
used in the oestrogen-dependent breast cancer therapy. It
has been recently tested on mice for its effect on AT metab-
olism and WAT browning (98). The study shows no acute
effects on body weight and food intake, but chronic tamox-
ifen administration affected the histology of subcutaneous
AT, by reducing the size of white adipocytes and increasing
the presence of brite adipocytes. Also lipid and glucose me-
tabolisms are affected (98).
Thiazolidinediones
The class of thiazolidinediones includes anti-hyperglicemic
drugs (i.e. rosiglitazone and pioglitazone) that participate
in BAT activation and WAT browning, acting as agonist li-
gands of PPARγ. Several in vitro studies show the ability
of rosiglitazone to promote the synthesis of UCP1 and other
mitochondrial proteins involved in electron transport chain
in both preadipocytes and mature adipocytes (99,100).
Nevertheless, the synthesis of UCP1 induced by
thiazolidinediones is not sufficient to trigger thermogenesis
in recruited cells, because a proper noradrenergic activation
is needed (18). In vivo rosiglitazone treatment on mice in-
creased UCP1 expression and lipid accumulation in brown
adipocytes, but failed in triggering thermogenesis, maybe
because of the downregulation of β3-ARs and DIO2
(101,102).
Pioglitazone treatment in cultured human subcutaneous
adipocytes led to a modest increase in UCP1 transcription
(103).
All pharmacological browning factors are summarized in
Table 2 and Fig. 2a.
Nutritional browning factors
Nutritional factors and nutraceuticals are gaining high in-
terest in obesity research, because many natural compounds
have been tested in a number of studies and show marked
lipolytic and/or anti-adipogenic activity (104,105).
Moreover, many molecules also have a positive effect on
thermogenesis and WAT browning.
Capsaicin and capsinoids
Capsaicin is an alkaloid present in plant species belonging
to the genus Capsicum, which includes the hot pepper. This
chemical compound is responsible for the burning sensation
of hot pepper, and its ability to induce WAT browning has
been known for many years. The exact mechanism of capsa-
icin action has been recently elucidated by Baskaran et al.
(106). The authors showed that in mice fed with a HFD,
capsaicin suppressed weight gain without affecting food






Mechanisms of action Effect Ref.
L-796568 β3-AR Selective β3-sympathomimetic Acute increase of thermogenesis 87–89
Mirabegron β3-AR Selective β3-sympathomimetic,
weak affinity to other β-
adrenoreceptors




Inhibition of the reuptake of
serotonin and norepinephrine
Appetite reduction, increase of thermogenesis, improvement of blood





Inhibition of the reuptake of
serotonin
Upregulation of UCP1, increase in BAT mass 95
Fenfluramine 5-HT
synapses
Increase of the synaptic release of
serotonin




Tamoxifen ER Agonist of oestrogen receptor Chronic scWAT browning. 98
Modification of lipid and glucose metabolism
Rosiglitazone PPARγ Agonist ligand of PPARγ Upregulation of UCP1 in preadipocytes and mature adipocytes 99,100
Downregulation of β3-AR and DIO2 101,102
Pioglitazone PPARγ Agonist ligand of PPARγ Modest upregulation of UCP1 103
5-HT, serotonin; β3-ARs, β3-adrenergic receptors; BAT, brown adipose tissue; DIO2, type II iodothyronine 5
0-deiodinase; ER, oestrogen receptor; NE, nor-
epinephrine; PPARγ, peroxisome proliferator-activated γ; scWAT, subcutaneous WAT; UCP1, uncoupling protein 1; WAT, white adipose tissue.
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intake, by overexpressing the transient receptor potential
cation channel, subfamily V, member 1 (TRPV1), which is
usually downregulated by HFD (106,107). The in vitro
analyses showed that capsaicin stimulates Ca2+ influx in
subcutaneous cultured adipocytes that express TRPV1.
The Ca2+ influx activates the Ca2+/calmodulin-dependent
protein kinase II, which in turn activates AMPK. This en-
zyme phosphorylates SIRT1, which deacetylates both
PPARγ and PRDM16. The interaction of these two tran-
scription factors increases their own stability. The final step
is the stimulation of the synthesis of UCP1 and BMP8B in
white adipocytes, with the consequent stimulation of
browning and thermogenesis. Capsaicin is also active at a
transcriptional level, because it increases the expression of
PPARα, PPARγ, SIRT1 and PGC-1α. The increased expres-
sion of PPARα is associated with an increased lipolytic
activity of the adipocyte (106).
Capsinoids, i.e. capsiate, dihydrocapsiate and
nordihydrocapsiate, are non-pungent analogues of capsai-
cin found in some Capsicum species (108,109). Despite
their structural affinity with capsaicin, these molecules show
some different behaviours in the organism. They are unsta-
ble in aqueous environment and rapidly hydrolyzed in the
gastrointestinal tract (110). Capsinoids are not detectable
in plasma after oral administration of a capsinoid-
supplemented diet to mice (111). The capsinoids binding
affinity to TRPV1 is similar to that of capsaicin, but the in-
flux of Ca2+ is almost 10 times lower (112). According to
these findings, Ohyama et al. (111) proposed a capsinoid’s
central-mediated signalling. This pathway involves the in-
teraction of capsinoids to gastrointestinal TRPV1 receptors
which in turn activate the vagal afferent nerves, which are
able to stimulate VMH. This stimulation triggers a
β2-adrenergical sympathetic response in WAT depots that
increase the stability and half-life of PRDM16 and that is
independent from cold-induced, β3-adrenergic stimulation.
So the two adrenergic pathways act on WAT browning in
a synergistic way.
Protoalkaloids of bitter orange
Synephrine alkaloids (SAs) are molecules that can be found
in fruits of bitter orange (Citrus aurantium L.). These mole-
cules are p-synephrine, often referred to as synephrine or
oxedrine, and m-synephrine, i.e. phenylephrine. The pres-
ence of both SAs in bitter orange fruit is subject to varia-
tions, i.e. m-synephrine is not always detected (113).
Synephrine alkaloids are sympathomimetics with non-
specific affinity for AR, as their structure is very similar to
that of NE and ephedrine. In detail, p-synephrine with α-
AR, β1-AR and β2-AR presents little binding affinity, being
Figure 2 (a) Pharmacological factors (light blue squares) involved in white adipose tissue browning and their cellular targets (blue circles). Receptors are
reported in cyan boxes. All blue arrows indicate a stimulatory effect. *The drug has been withdrawn from the market. (b) Nutritional factors (light green
squares) involved in white adipose tissue browning and their cellular targets (blue circles). Receptors are reported in green boxes. The pathways that di-
rectly participate to upregulation of UCP1 (yellow circle) are reported along the brown arrow. All green arrows indicate a stimulatory effect. β3-ARs, β3-ad-
renergic receptors; AMPK, cAMP-activated protein kinase; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FX, fucoxanthin; PKA, protein
kinase A; PPAR, peroxisome proliferator-activated receptor; TRPM8, transient receptor potential cation channel subfamily M, member 8; TRPV1, transient
receptor potential cation channel, subfamily V, member 1; Rald, retinaldehyde; SIRT1, silent information regulator type 1; UCP1, uncoupling protein 1.
[Colour figure can be viewed at wileyonlinelibrary.com]
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the β3-ARs the most likely preferential target (114). On the
contrary, m-synephrine evidences affinity with the α-AR,
β1-AR and β2-AR. However, m-synephrine and
p-synephrine are, respectively, 100-fold and 40,000-fold
less potent than NE in binding β1-AR and β2-AR (114).
Studies report the lipolytic effect of p-synephrine in both
rat and human adipocytes, with stronger outcome in rat
cells (115). Moreover, this alkaloid is also active on rat
hepatic carbohydrate metabolism, as shown by liver perfu-
sion with bitter orange extract (116) and with pure p-
synephrine (115). SAs stimulate glycogenolysis, glycolysis,
gluconeogenesis and oxygen uptake in hepatocytes through
α-adrenergic and β-adrenergic stimulation, with higher
extent of α-ARs stimulation.
The fluctuating binding capacity of SAs to different iso-
forms of ARs raised high concern about the safety of these
molecules from a cardiovascular point of view. In this re-
gard, Haaz et al. (117) extensively reviewed clinical studies
and case reports showing a lack of significant data due to
suboptimal planning of administrations and trials.
The alkaloid p-octopamine is also present in bitter or-
ange fruit in lower concentration than p-synephrine. It is
preferentially a β3-adrenergic agonist, and it induces lipol-
ysis and browning in white rat adipocytes but not in hu-
man cells (118). A comparative study between rat and
human adipocytes highlights the lipolytic effect of several
C. aurantium alkaloids, the most active being p-synephrine
thanks to its higher concentration in the bitter orange
extract (119).
A synthetic derivative of SAs, isopropylnorsynephrine,
has a more powerful lipolytic effect compared to natural-
occurring compounds. The study conducted by Mercader
et al. (119) infers a specific β3-adrenergic agonism for this
molecule; hence theoretically, cardiovascular side effects
should be negligible compared to non-selective sympatho-
mimetic alkaloids. Therefore, isopropylnorsynephrine could
be an interesting anti-obesity molecule candidate, pending
further testing (119).
Fucoxanthin
Fucoxanthin (FX) is an isoprenoid molecule found in many
edible seaweeds, with the highest levels found in the diatom
Phaeodactylum tricornutum (120). It has a manifold benefi-
cial role in the control of adiposity and carbohydrate metab-
olism; hence, it is used as a protective functional ingredient
against weight gain and metabolic disorders.
Administration of FX significantly downregulates the ex-
pression and activity of lipogenic enzymes, while
upregulates oxidative pathways of fatty acids (FAs) and
the expression of β3-ARs in adipocytes (120). This induces
an increase of UCP1 expression in both, WAT and BAT
(121,122).
Fucoxanthin effects may be potentiated through the com-
bination with other lipophilic substances such as medium-
chain triglycerides (123), conjugated linoleic acid (124),
fucoxanthinol (which is a deacetylated FX-derivative)
(125) and fish oil (126). Xanthigen is a dietary product that
includes fucoxanthin and pomegranate seed oil, which is
rich in ω5 punicic acid (127). A recent pilot study, using
18F-fluorodeoxyglucose positron emission tomography,
demonstrates that chronic administration of Xanthigen in
a premenopausal, obese woman activates BAT in cervical,
supraclavicular and paravertebral areas (128).
Fucoxanthin is accumulated in form of different metabo-
lites: in heart and liver as fucoxanthinol and in AT as
amarouciaxanthin A. These metabolites are very effective
in inhibiting the differentiation of white preadipocytes into
mature white adipocytes (129,130).
Fucoxanthin also improves blood parameters and hepatic
accumulation of lipids (131,132).
Carotenoids and related compounds and
metabolites
Carotenoids include a broad spectrum of C40 isoprenoid
compounds which affect AT biology either directly or
through their metabolic products, i.e. retinoids. The most
important carotenoid is pro-vitamin A β-carotene (BC),
which can be metabolized in adipocytes by the enzymes
β-carotene-15,150-oxygenase (BCO1) and β-carotene-
90,100-oxygenase (BCO2) (which are differentially
expressed in subcutaneous and visceral AT) (133) to gener-
ate several cleavage products, including retinoic acid (RA)
and relative isomers, retinaldehyde (Rald) and several β-
apocarotenals and β-apocarotenones (134). The effects of
carotenoids and retinoids on AT mostly rely on their ability
to bind to specific nuclear receptors, namely RA receptors
(RARs) and retinoid X receptors (RXRs), in order to mod-
ulate gene expression in the adipocyte. All-trans RA (atRA)
is a ligand of RARs, while 9-cis RA binds both RARs and
RXRs. Activated RARs achieve their effect on gene expres-
sion by forming a heterocomplex with RXRs. In turn,
RXRs may interact also with other nuclear receptors, in-
cluding TRs and PPARs (134). Besides retinoid receptors,
other receptors represent potential targets for retinoids
and carotenoids: atRA, Rald, several apocarotenoids and
astaxanthin act as enhancers or inhibitors of PPAR
isoforms (134). Also extranuclear, non-genomic effects
are achieved by these compounds through Janus kinase 2
signalling pathway (135).
Effects of carotenoids and retinoids in counteracting lipid
accumulation and preadipocyte differentiation have been
studied in both, in vitro and in vivo models and have been
extensively reviewed by Bonet et al. (134). A number of
studies report also an effect of carotenoid-related com-
pounds in increasing energy expenditure and thermogenesis
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in both WAT and BAT. The participation of BC in the mod-
ulation of UCP1 expression was early established by in vitro
studies (136), and it is due to the conversion of BC and
other pro-vitamin A carotenoids into atRA, whose interac-
tion with RARs strongly triggers UCP1 synthesis. The
non-metabolized form of BC is not active on UCP1 expres-
sion and WAT browning (19).
All-trans RA treatment of murine white fat cells induced
the overexpression of thermogenic and catabolic proteins
and the increase in mitochondrial biogenesis. These effects
seem to be promoted by lipocalin 2, a recently discovered
adipokine which is involved in the regulation of the cellular
uptake and metabolism of retinoids (137). The same mole-
cule was tested on human SGBS cell line, multipotent
adipose-derived stem cells and primary preadipocyte cell
culture; the experiment shows no effect of atRA in inducing
UCP1 synthesis and WAT browning in any of these cell cul-
ture models (138).
A role in WAT browning has been attributed also to Rald,
independently of its conversion to atRA (134).
Long chain (poly)unsaturated fatty acids
As previously highlighted in this review, an excess in dietary
arachidonic acid leads to an increased WAT adipogenesis,
flanked by a reduction in BAT functionality andWAT brow-
ning (69). This is true for other ω6 polyunsaturated fatty
acids (PUFAs) as well. Nowadays, food habits privilege the
intake of ω6 PUFAs rather than ω3 ones, and the prevalence
of dietary ω6 PUFAs has been proposed to be detrimental
because of its adverse effects on lipid metabolism and obe-
sity development. Several studies have investigated the role
of PUFAs on AT from metabolic and genomic point of view,
and these findings have been comprehensively reviewed by
Simopoulos (139).
Eicosapentaenoic acid and docosahexaenoic acid are ω3
PUFAs abundantly present in fish oil. They are known to
reduce and prevent weight gain through their positive ac-
tion on PPAR members expression in BAT, which leads to
an increase in metabolism of glucose and FAs (140). A
study on mice reveals that ω3 PUFAs activate thermogene-
sis, as the reduction of body weight is not accompanied by
a diminished food intake (141). Dietary eicosapentaenoic
acid and docosahexaenoic acid (administered in daily doses
ranging from 119 to 238 g kg1) increase the expression of
UCP1, PPARs and β3-AR genes, which are directly in-
volved in thermogenesis, and of other genes involved in
the uptake and metabolism of glucose and FAs (i.e.
GLUT4, CD36 and CPT1) (141). These observations were
confirmed by in vitro studies on human adipose-derived
stem cells (142).
Conjugated linoleic acid (CLA) is a mixture of linoleic
acid isomers which are naturally present in cow milk. CLA
effects on lipid metabolism, AT inflammation and
thermogenesis are reviewed in detail by Shen and McIntosh
(143). A number of studies reveal that CLA has a great po-
tential to reduce adiposity and trigger browning especially
in visceral WAT, through G protein-coupled receptors and
noradrenergic stimulation of AT. However, the long-term
effects of CLA-induced WAT browning may harm the de-
fence of body temperature (143).
Chemical modification of dietary FAs has shown benefi-
cial effects on health in several cases (144,145). 2-
hydroxyoleic acid is formed by addition of hydroxylic
group in α position of oleic acid and possesses an ability
to induce thermogenesis by upregulating UCP1 expression.
Normal oleic acid also causes body weight reduction in rats
but does not affect UCP1 expression (146).
Polyphenolic and non-aromatic alcoholic
compounds
Polyphenols are aromatic molecules found in plants charac-
terized by the presence of multiples of phenol structural
units. Thymol, although having a single aromatic group, is
included in this category. Thymol, found in thyme species
(Thymus spp.) has recently been tested as an anti-obesity
compound (147) and as activator of thermogenesis (148).
A recent study on 3T3-L1 murine adipocytes shows that
thymol, acting as a β3-adrenergic agonist, promotes lipoly-
sis, FA oxidation, expression of UCP1 and mitochondrial
biogenesis (148). Interestingly, its isomer carvacrol, also
found in thyme, has anti-obesity properties as well but
cannot stimulate thermogenesis (149).
Resveratrol is a polyphenol present in the skin of grapes
(Vitis vinifera L.) and in other fruit species with known ben-
eficial effects on adiposity and metabolic disorders
(150,151). The effect of resveratrol in AT biology is due
to its ability to activate AMPK (152). In murine primary
stromal vascular cells separated from inguinal WAT, res-
veratrol induces browning of WAT through AMPK-
dependent pathway that leads to the increase of UCP1
mRNA and protein content in white adipocytes and en-
hances the expression of a number of brite-specific gene
markers (153).
Oleuropein is a polyphenolic glycoside present in extra
virgin olive oil. It is present also as an aglycone and gives
a pungent taste to olive oil. It has been recognized as a pow-
erful antioxidant compound and also has anti-obesity prop-
erties, like many other molecules detected in olive oil,
including hydroxytyrosol (154–156). Studies on rats con-
firmed that anti-obesity effect of oleuropein and oleuropein
aglycone is achieved through the activation of thermogene-
sis in BAT and an increased release of both epinephrine
and NE, which in turn activates lipolytic pathways in AT.
Interestingly, these molecules, and in particular oleuropein
aglycone, are agonists of the capsaicin receptor TRPV1;
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hence, their anti-obesity effect could be comparable to that
of capsaicin (157).
Curcumin is a polyphenolic compound extracted from
Curcuma longa L. with well documented beneficial effects
for a wide spectrum of diseases (158–160). In 3T3-L1 cells
and rat primary inguinal white adipocytes, curcumin stimu-
lates lipolysis and induces a brite phenotype through an
AMPK-dependent mechanism that influences the expression
of UCP1 and brite gene markers (161). The role of curcumin
in WAT browning was previously reported by Wang et al.
(162) in mice. They inferred an NE-dependent pathway be-
cause, after curcumin administration, plasma NE levels and
the expression of β3-ARs in WAT increase in mice.
Other polyphenolic compounds can be found in tea
(Camellia sinensis (L.) Kuntze). The positive effect of tea on
energy expenditure and thermogenesis has been known,
Table 3 Nutritional factors involved in BAT development and recruitment, WAT browning and UCP1 upregulation. Side effects of natural compounds are
reported in italic
Browning factors Source Cellular
target
Mechanisms of action Effect Ref
Capsaicin Capsicum spp. TRPV1 CaMKII/AMPK/SIRT1-dependent
deacetylation of PPARγ and PRDM16
Upregulation of UCP1 and BMP8B 106
Capsiate Capsicum
annuum
TRPV1 TRPV1/VMH-mediated increase of β2-
adrenergic stimulation









p-octopamine β3-AR Selective β3-sympathomimetic, weak
affinity to other β-adrenoreceptors
Induction of lipolysis and browning in
non-human WAT
118,119





Downregulation of lipogenic enzymes Inhibition of adipogenesis 120–122






BCO1 Conversion into retinoids and
apocarotenoids
Indirect WAT browning 134,136–
138Astaxanthin BCO2
All-trans retinoic acid Carotenoid
metabolism
RAR Lipocalin 2-driven regulation of gene
transcription
Upregulation of UCP1
9-cis retinoic acid RXR
Retinaldehyde RAR
Aldh1a1 Conversion into all-trans retinoic acid
Eicosapentaenoic acid Fish oil PPARα Agonists of PPARα and PPARγ Increase in glucose and lipid






Cow milk GPCR NE-dependent activation of adipocyte Selective browning of omWAT 143
2-hydroxyoleic acid Synthetic ? Upregulation of UCP1 Induction of WAT browning 146
Thymol Thymus spp. β3-AR Selective β3-sympathomimetic Promotion of lipolysis and lipid oxidation 147,148
Upregulation of UCP1
Mitochondrial biogenesis
Resveratrol Vitis vinifera AMPK Activation of AMPK-dependent signal
pathways
Upregulation of UCP1 and of brite-
specific markers
152,153
Oleuropein Olea europaea TRPV1 Not described Upregulation of UCP1 157
Oleuropein aglycone Increase of epinephrine and NE release
Curcumin Curcuma longa AMPK Activation of AMPK-dependent signal
pathways





AMPK Activation of AMPK-dependent signal
pathways




L-menthol Mentha spp. TRPM8 Ca
2+
-dependent phosphorylation of
PKA and activation of downstream
pathways
Upregulation of UCP1 169,171
TRPA1 Mitochondrial biogenesis
Ginsenoside Rb1 Panax spp. PPARγ Agonist of PPARγ Upregulation of UCP1 172
α-ARs, α-adrenergic receptors; β3-adrenergic receptors; Aldh1a1, aldehyde dehydrogenase 1A1; AMPK, cAMP-activated protein kinase; BAT, brown ad-
ipose tissue; BCO1, β-carotene-15,150-oxygenase; BCO2, β-carotene-90,100-oxygenase; BMP, bone morphogenetic protein; GPRC, G protein–coupled re-
ceptors; NE, norepinephrine; omWAT, omental WAT; PPARγ, peroxisome proliferator-activated γ; PKA, protein kinase A; PRDM16, PR/SET domain 16;
RAR, retinoic acid receptor; RXR, retinoid X receptor; SIRT1, silent information regulator type 1; TRPM8, transient receptor potential cation channel subfam-
ily M, member 8;TPRV1, transient receptor potential cation channel, subfamily V, member 1; UCP1, uncoupling protein 1; VMH, ventromedial hypothala-
mus; WAT, white adipose tissue.
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and it has been attributed to its caffeine content. In 2000,
Dulloo et al. (163) showed that the thermogenic potential of
green tea extract cannot be explained by the sole presence
of caffeine, as also catechins participate in BAT activation.
Among these, epigallocatechin 3-gallate is themost abundant
in green tea leaves (163,164). The oral administration of
encapsulated green tea and Guaraná extracts to humans
showed a synergistic role of caffeine and epigallocatechin 3-
gallate in acutely activating thermogenesis and energy
expenditure (165).
A recent study conducted on mice demonstrated that
decaffeinated green tea has also anti-obesity properties, so
the presence of caffeine would not be mandatory to achieve
thermogenic activation (166). However, in this study, the
administration of decaffeinated green tea was combined
also with physical exercise; therefore, the observed thermo-
genic activation could be due to the effect of myokines se-
creted by muscle rather than to the only decaffeinated
green tea.
Depending on the level of oxidation and fermentation,
teas contain caffeine and different amounts of polyphenolic
molecules, as catechins and theaflavins. While green tea is
rich in catechins, black tea has a higher content of
theaflavins that were responsible to the AMPK activation
in obese mice fed with black tea (167). Phytochemicals of
teas exert their anti-obesity effect through the activation of
AMPK, which in turn triggers the overexpression of differ-
ent anti-adipogenic genes, including those promoting the
development of a brown-like phenotype in white adipo-
cytes, especially UCP1 and the other uncoupling proteins
(168).
L-menthol is an alcoholic cooling chemical present in
mint oils (Mentha spp.), which is an agonist of the transient
receptor potential cation channel subfamily M, member 8
(TRPM8). This is a cold receptor recently found on plasma
membrane of both brown and white adipocytes (169,170).
Preliminary in vitro and in vivo studies showed that the
stimulation of adipose TRPM8 with L-menthol triggers an
overexpression of UCP1 and an increase in mitochondrial
biogenesis and electrochemical potential, which results in
an increase of thermogenesis and WAT browning (171).
The cellular mechanism is NE-independent, as the activa-
tion of TRPM8 induces the phosphorylation of PKA via a
Ca2+ influx (169). L-menthol can bind also to another
plasma membrane receptor, the transient receptor potential
cation channel subfamily A, member 1, but its role in the
thermogenic response is still controversial (171). Hence,
L-menthol is a potential candidate for the anti-obesity
therapy, but further research is needed.
Ginsenoside Rb1 is a sterol-like-structured molecule
extracted from plants belonging to the genus Panax that
includes several ginseng species. In 3T3-L1 adipocytes,
ginsenoside Rb1 induces WAT browning through an in-
creased PPARγ-mediated UCP1 expression (172).
All nutritional browning factors are summarized in
Table 3 and Fig. 2b.
Conclusions
The activation of BAT and the recruitment of brite adipo-
cytes in adult humans have gained outstanding interest in
obesity research, as nowadays the role of BAT in
counteracting the accumulation of excess energy and pro-
moting energy expenditure is well established (173) Indeed,
in the last years, the involvement of brown and brite adipo-
cytes in stimulating energy expenditure through the activa-
tion of both cold-induced and diet-induced thermogenesis
has been confirmed (173–176). Using positron emission to-
mography, it was demonstrated that in adult humans, the
acute cold exposure effectively triggers BAT oxidative me-
tabolism with an increase in total energy expenditure
(177). Nevertheless, as highlighted in the present review,
also many endogenous and exogenous factors could effec-
tively trigger WAT browning, through the activation of dif-
ferent cellular pathways, producing a significant outcome in
BAT activation and brite cell recruitment. However, as re-
ported by Chechi et al. (175), it should be considered that
BAT activation could activate important metabolic adapta-
tions that counteract the weight loss. Moreover, in mice
subjected to chronic cold exposure and adrenergic stimula-
tion, inguinal WAT depot shows a lower increase of oxida-
tive metabolism and energy expenditure than iBAT (178).
These features open questions about the significance of the
increase in energy expenditure and thermogenesis generated
by brite adipocytes or by BAT activation.
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